Labcorp Expands Oncology Portfolio to Improve Patient Care and Advance Cancer Research
- New test offerings target solid tumors and hematologic malignancies Enhanced biopharma services support accelerated clinical trials and companion diagnostic development BURLINGTON, N.C. , May 30, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology portfolio.
- 05/30/2025
|
Why Is Labcorp (LH) Up 2.5% Since Last Earnings Report?
- Labcorp (LH) reported earnings 30 days ago. What's next for the stock?
- 05/29/2025
|
LH or SAUHY: Which Is the Better Value Stock Right Now?
- Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Labcorp (LH) or Straumann Holding AG (SAUHY). But which of these two stocks presents investors with the better value opportunity right now?
- 05/28/2025
|
Are Investors Undervaluing Labcorp (LH) Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 05/28/2025
|
Here's Why Labcorp (LH) is a Strong Value Stock
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 05/19/2025
|
Here's Why Labcorp (LH) is a Strong Momentum Stock
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 05/15/2025
|
3 Dental Supplies Stocks Likely to Gain From US-China Trade Deal
- Here we discuss three stocks from the Dental Supplies industry that are likely to earn wealth for investors. These are CAH, LH and ALGN.
- 05/13/2025
|
Should Value Investors Buy Labcorp (LH) Stock?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 05/12/2025
|
Labcorp to Webcast Its Annual Meeting of Shareholders May 15
- BURLINGTON, N.C., May 8, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that its Annual Meeting of Shareholders will be webcast live on May 15 at 9:00 a.m.
- 05/08/2025
|
LH vs. MMSI: Which Stock Is the Better Value Option?
- Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Labcorp (LH) and Merit Medical (MMSI). But which of these two stocks offers value investors a better bang for their buck right now?
- 05/05/2025
|
Why Labcorp (LH) is a Top Value Stock for the Long-Term
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 05/01/2025
|
Labcorp Holdings Inc. (LH) Q1 2025 Earnings Call Transcript
- Labcorp Holdings Inc. (NYSE:LH ) Q1 2025 Earnings Conference Call April 29, 2025 9:00 AM ET Company Participants Christin O'Donnell - Investor Relations Adam Schechter - Chairman & Chief Executive Officer Julia Wang - Executive Vice President & Chief Financial Officer Conference Call Participants Michael Cherny - Leerink Partners Ann Hynes - Mizuho Securities Erin Wright - Morgan Stanley Elizabeth Anderson - Evercore ISI Lisa Gill - JPMorgan Jack Meehan - Nephron Research Luke Sergott - Barclays Kevin Caliendo - UBS Michael Ryskin - Bank of America Patrick Donnelly - Citi Eric Coldwell - Baird Kieran Ryan - Deutsche Bank Operator Good day and thank you for standing by. Welcome to the Q1 2025 Labcorp Holdings Earnings Conference Call.
- 04/29/2025
|
Labcorp (LH) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
- Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 04/29/2025
|
Labcorp Q1 Earnings Surpass Estimates, Revenues Miss, Stock Gains
- LH delivers better-than-expected earnings in the first quarter of 2025.
- 04/29/2025
|
Labcorp (LH) Beats Q1 Earnings Estimates
- Labcorp (LH) came out with quarterly earnings of $3.84 per share, beating the Zacks Consensus Estimate of $3.73 per share. This compares to earnings of $3.68 per share a year ago.
- 04/29/2025
|
Labcorp Announces 2025 First Quarter Results
- Updates Full-Year Guidance Results from Operations for first quarter 2025 versus first quarter last year: Revenue: $3.35 billion versus $3.18 billion Diluted EPS: $2.52 versus $2.69 Adjusted EPS: $3.84 versus $3.68 Reaffirmed Revenue and Free Cash Flow guidance, raised midpoint of adjusted EPS: Revenue guidance of 6.7% to 8.0% Adjusted EPS range of $15.70 to $16.40; midpoint raised $0.05 Free Cash Flow of $1.10 billion to $1.25 billion Providing broader access to comprehensive testing and laboratory services with several transactions announced/completed year-to-date Introduced new tests including Labcorp Plasma Complete, a liquid biopsy test for cancer, and pTau-217/Beta Amyloid 42 Ratio test to aid in the diagnosis of Alzheimer's disease BURLINGTON, N.C. , April 29, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the first quarter ended March 31, 2025 and updated full-year guidance.
- 04/29/2025
|
Labcorp Launches Molecular Residual Disease and Liquid Biopsy Solutions
- Labcorp® Plasma Detect™ now available for clinical use to assess risk of recurrence in stage III colon cancer patients FDA-authorized liquid biopsy assay PGDx elio® plasma focus™ Dx now available to support treatment selection BURLINGTON, N.C. , April 23, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology portfolio with two solutions: Labcorp Plasma Detect for clinical use to help assess the risk of disease recurrence in stage III colon cancer patients, and the availability of PGDx elio plasma focus Dx, the first and only kitted, pan-solid tumor liquid biopsy test authorized by the U.S. Food and Drug Administration (FDA) to identify patients who may benefit from targeted treatments.
- 04/23/2025
|
Labcorp (LH) Earnings Expected to Grow: Should You Buy?
- Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/22/2025
|
Labcorp Q1 Earnings Preview: Diagnostics Arm Likely to Drive Growth
- LH's first-quarter 2025 performance is likely to have benefited from both its Dx and BLS businesses.
- 04/16/2025
|
Genetic Screening Testing for the Preventive Health Market, 2025-2035 Analysis - Dominated by Exact Science, Labcorp Genetics, Blueprint Genetics, Ambry Genetics, and Genex Diagnostics
- Dublin, April 11, 2025 (GLOBE NEWSWIRE) -- The "Genetic Screening Testing for Preventive Health Market - A Global and Regional Analysis: Focus on Test Type, Technology, Application, End User and Country-Level Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The market for genetic screening testing in preventive health has been experiencing rapid growth, driven by driving factors such as technological advancements, increased consumer interest in personalized medicine, and the rise of preventive healthcare strategies. Several key factors influence the expansion of the genetic screening testing for preventive health market. Improvements in genetic testing technologies, such as next-generation sequencing (NGS), have made these tests more accessible, cost-effective, and accurate. Growing consumer awareness of the benefits of early detection, rising healthcare costs, and an increasing focus on prevention have further fuelled the demand. Moreover, the increasing availability of direct-to-consumer genetic tests has allowed individuals to manage their health. Stakeholders in this market include genetic testing companies, healthcare providers, hospitals, diagnostic laboratories, and wellness-focused organizations. As more people seek personalized, data-driven approaches to healthcare, the demand for genetic screenings as a preventive tool is expected to increase. Moreover, the growing availability of direct-to-consumer genetic testing kits has empowered individuals to take charge of their health and gain insights into their genetic predispositions without necessarily needing a healthcare provider. This trend has significantly expanded the genetic screening market, allowing consumers to access preventive health information more easily. The genetic screening testing for preventive health market is set to witness substantial growth. With continued technological advancements and growing public interest in health optimization and disease prevention, the market offers significant opportunities for healthcare, biotechnology, and wellness stakeholders to meet the rising demand for personalized, proactive health solutions. The development of next-generation sequencing (NGS) technologies and improvements in bioinformatics have made genetic testing more accurate, efficient, and affordable. These innovations allow for comprehensive genetic analysis, enhancing the ability to detect predispositions to various diseases at earlier stages. The continuous evolution of these technologies further drives the demand for genetic screening services in preventive healthcare. Furthermore, there is a growing recognition of the importance of preventive healthcare, with more individuals understanding the benefits of early disease detection and management. Public health campaigns, medical professionals, and organizations have been emphasizing the value of genetic screening to detect health risks before symptoms appear, further driving market demand.
- 04/11/2025
|
Labcorp Declares Quarterly Dividend
- BURLINGTON, N.C. , April 10, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock.
- 04/10/2025
|
Is it the Right Time to Retain Labcorp Stock in Your Portfolio?
- LH's growth opportunities in important specialty testing areas are robust. Expanding through strategic acquisitions is an added plus.
- 04/09/2025
|
Here's Why Labcorp (LH) is a Strong Growth Stock
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 04/03/2025
|
LH Stock to Gain From Launch of HPV and STI Self-Collection Options
- Labcorp launches self-collection options for HPV and STI testing in its PSCs.
- 04/02/2025
|
Labcorp Launches First-of-its-Kind Immunoassay to Accelerate Path to Diagnosis of Alzheimer's Disease
- Labcorp's pTau-217/Beta Amyloid 42 Ratio blood test meets the performance criteria to confirm amyloid pathology consistent with Alzheimer's disease BURLINGTON, N.C. , April 2, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide launch of its pTau-217/Beta Amyloid 42 Ratio, a powerful new blood-based biomarker test to aid in the diagnosis of Alzheimer's disease.
- 04/02/2025
|
Labcorp to Offer HPV and STI Self-Collection Options in Labcorp Patient Service Centers and Participating Physician Offices Nationwide
- New offering expands screening options for cervical cancer and sexually transmitted infections (STIs), including chlamydia, gonorrhea, trichomonas or mycoplasma genitalium (Mgen) BURLINGTON, N.C. , April 1, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer nationwide a U.S. Food and Drug Administration (FDA) approved human papillomavirus (HPV) self-collection solution that can help women and their physicians asses the risk of developing cervical cancer.
- 04/01/2025
|
Labcorp to Announce First Quarter Financial Results on April 29, 2025
- BURLINGTON, N.C. , March 31, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2025 before the market opens on Tuesday, April 29, 2025.
- 03/31/2025
|
Why Labcorp (LH) is a Top Growth Stock for the Long-Term
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 03/18/2025
|
Labcorp is Set to Acquire Select Assets of BioReference Health of OPK
- LH inks new agreement to acquire BioReference Health's oncology and related clinical testing services businesses.
- 03/14/2025
|
Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses
- Transaction to extend Labcorp's leadership in oncology and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI , March 11, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health.
- 03/11/2025
|
Should Labcorp Stock Stay in Your Portfolio Right Now?
- LH stays on investors' radar owing to its strong focus on high-growth areas and pursuing strategic acquisitions.
- 03/06/2025
|
Here's Why Labcorp (LH) is a Strong Value Stock
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 02/26/2025
|
Labcorp Announces Clinical Availability of Liquid Biopsy Test to Guide Personalized Treatment Plans for Patients with Advanced Solid Tumors
- Labcorp® Plasma CompleteTM offers oncologists a highly sensitive and specific genomic profiling solution from a simple blood draw BURLINGTON, N.C. , Feb. 24, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the clinical availability of Labcorp® Plasma CompleteTM , a circulating tumor DNA (ctDNA)-based comprehensive genomic profiling solution for patients with advanced solid tumors.
- 02/24/2025
|
Labcorp Holdings: Focus On Core Strengths For Future Growth, Initiate At 'Hold'
- Labcorp Holdings Inc., a leader in life sciences and diagnostics, is efficiently managing its financials and focusing on core strengths for long-term growth, warranting a “Hold” rating. Competitive advantages include large scale, diversified business model, strong industry relationships, and operational efficiency, driving strong revenue and margin expansion. Recent strategic initiatives like the Fortrea spin-off, Invitae acquisition, and SYNLAB stake enhance Labcorp's core business and future growth prospects.
- 02/13/2025
|
Why Labcorp (LH) is a Top Momentum Stock for the Long-Term
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 02/12/2025
|
Are Investors Undervaluing Labcorp (LH) Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 02/11/2025
|
Here's Why Labcorp (LH) is a Strong Growth Stock
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 02/11/2025
|
Why Labcorp (LH) is a Top Value Stock for the Long-Term
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 02/10/2025
|
Labcorp Holdings Inc. (LH) Q4 2024 Earnings Call Transcript
- Labcorp Holdings Inc. (NYSE:LH ) Q4 2024 Earnings Conference Call February 6, 2025 9:00 AM ET Company Participants Christian O'Donnell - IR Adam Schechter - Chairman and CEO Julia Wang - EVP and CFO Conference Call Participants Michael Cherny - Leerink Partners Jack Meehan - Nephron Research Lisa Gill - JP Morgan Erin Wright - Morgan Stanley Andrew Brackmann - William Blair Pito Chickering - Deutsche Bank Patrick Donnelly - Citi Kevin Caliendo - UBS David Westenberg - Piper Sandler Tycho Peterson - Jefferies Operator Good day, and thank you for standing by. Welcome to Labcorp's Fourth Quarter 2024 Conference Call [Operator Instructions].
- 02/06/2025
|
Labcorp Q4 Earnings: Revenue And EPS Beat, Expects Strong 2025 Growth, Analyst Reiterates Outperform On Stable 2025 Outlook
- Thursday, Laboratory Corp (NYSE: LH) reported fourth-quarter 2024 adjusted earnings per share of $3.45, up from $3.30 a year ago, beating the consensus of $3.39.
- 02/06/2025
|
Compared to Estimates, Labcorp (LH) Q4 Earnings: A Look at Key Metrics
- Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 02/06/2025
|
Labcorp Q4 Earnings & Revenues Beat, Margins Down, Stock Tumbles
- LH delivers better-than-expected revenues and earnings in the fourth quarter of 2024.
- 02/06/2025
|
Labcorp (LH) Q4 Earnings and Revenues Surpass Estimates
- Labcorp (LH) came out with quarterly earnings of $3.45 per share, beating the Zacks Consensus Estimate of $3.40 per share. This compares to earnings of $3.30 per share a year ago.
- 02/06/2025
|
Labcorp forecasts 2025 revenue above estimates on diagnostic test demand
- Labcorp forecast 2025 revenue above Wall Street estimates after reporting fourth-quarter results beat on Thursday, banking on robust demand for its diagnostic tests.
- 02/06/2025
|
Labcorp Announces 2024 Fourth Quarter and Full Year Results
- Company Provides 2025 Guidance Results from Continuing Operations versus last year: Revenue: Q4 of $3.33 billion vs $3.03 billion; Full year of $13.01 billion vs $12.16 billion Diluted EPS: Q4 of $1.70 vs $(1.95); Full year of $8.84 vs $4.33 Adjusted EPS: Q4 of $3.45 vs $3.30; Full year of $14.57 vs $13.56 Free Cash Flow: Q4 of $665.1 million vs $412.4 million; Full year of $1.10 billion vs $748.7 million Announced 10 transactions and launched new innovative tests meeting significant unmet medical needs in key specialty areas in full year 2024 Full-Year 2025 Guidance: Revenue of $13.88 billion to $14.05 billion; midpoint growth of 7.4% Adjusted EPS of $15.60 to $16.40; midpoint growth of 9.8% Free Cash Flow of $1.10 billion to $1.25 billion; midpoint growth of 7.2% BURLINGTON, N.C. , Feb. 6, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the fourth quarter ended December 31, 2024, and provided 2025 guidance.
- 02/06/2025
|
Labcorp (LH) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
- Beyond analysts' top -and-bottom-line estimates for Labcorp (LH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
- 02/04/2025
|
Labcorp Set to Report Q4 Earnings: What's in Store for the Stock?
- In the fourth quarter of 2024, LH is likely to have witnessed strong growth in both diagnostics and biopharma laboratory services.
- 01/31/2025
|
Labcorp (LH) Earnings Expected to Grow: Should You Buy?
- Labcorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 01/30/2025
|
LH or ALGN: Which Is the Better Value Stock Right Now?
- Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Labcorp (LH) or Align Technology (ALGN). But which of these two companies is the best option for those looking for undervalued stocks?
- 01/29/2025
|
Labcorp to Speak at the 43rd Annual J.P. Morgan Healthcare Conference
- BURLINGTON, N.C. , Jan. 10, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that the company will participate in a fireside chat at the 43rd Annual J.P.
- 01/10/2025
|
Why Labcorp (LH) is Poised to Beat Earnings Estimates Again
- Labcorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 01/09/2025
|
LABCORP DECLARES QUARTERLY DIVIDEND
- BURLINGTON, N.C. , Jan. 8, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock.
- 01/08/2025
|
Labcorp to Announce Fourth Quarter Financial Results on February 6, 2025
- BURLINGTON, N.C. , Jan. 8, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter of 2024 before the market opens on Thursday, February 6, 2025.
- 01/08/2025
|
LH vs. WST: Which Stock Is the Better Value Option?
- Investors interested in Medical - Dental Supplies stocks are likely familiar with Labcorp (LH) and West Pharmaceutical Services (WST). But which of these two companies is the best option for those looking for undervalued stocks?
- 01/03/2025
|
Is Labcorp (LH) Stock Undervalued Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 01/03/2025
|
Should You Retain Labcorp Stock in Your Portfolio Right Now?
- Investors are increasingly optimistic about LH due to its focus on high-growth areas and strategic partnerships.
- 01/03/2025
|
Labcorp's New Alliance With Graves Gilbert Clinic Set to Boost Stock
- LH announces strategic agreement with Graves Gilbert Clinic for lab operations.
- 12/26/2024
|
Labcorp Launches H5 Bird Flu Test Amid US Outbreak: Stock to Gain?
- LH's new H5 bird flu test, developed in collaboration with the CDC, is now available in the United States.
- 12/19/2024
|
LH Stock May Gain From Select MAWD Pathology Asset Purchase Deal
- Labcorp is set to acquire select assets of MAWD Pathology Group.
- 12/17/2024
|
Labcorp Launches H5 Bird Flu Test in the U.S., Now Available for Order through Physicians
- New test supports public health preparedness efforts and testing infrastructure amid multistate outbreak of H5 bird flu in poultry and dairy cows BURLINGTON, N.C. , Dec. 17, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the commercial availability of its new H5 bird flu molecular test to aid in the diagnosis of human infection with H5 bird flu.
- 12/17/2024
|
Be Patient, Earn Dividends From Labcorp, The Leading Patient Clinical Lab Brand
- For my initial coverage of Labcorp, I'm calling it a hold, and an opportunity to earn a $0.72/share quarterly dividend on the leading clinical lab company in the US. The firm shows future growth indicators through the growth of new locations and acquisitions, but also expected future patient demand for diagnostics. The company's main competitor/peer in this niche is Quest Diagnostics, and Labcorp struggles with a weak profit margin and growth in expenses.
- 11/29/2024
|
Outcomes4Me and Labcorp Study Reveals Digital Education Can Increase HER2-low Awareness for Metastatic Breast Cancer Patients
- Research to be presented in a joint poster session with Labcorp at the 2024 San Antonio Breast Cancer Symposium BOSTON and BURLINGTON, N.C. , Nov. 26, 2024 /PRNewswire/ -- Outcomes4Me Inc., the developer of the first and only end-to-end, actionable cancer platform, announced today it has been selected to present the results of a biomarker awareness study, conducted with Labcorp, a global leader of innovative and comprehensive laboratory services, at the prestigious 2024 San Antonio Breast Cancer Symposium (SABCS) on December 13, 2024.
- 11/26/2024
|
Cinven secures Italian nod to sell minority stake in Synlab to Labcorp
- Private equity firm Cinven secured a conditional approval from Italian authorities over its plan to sell a 15% stake in diagnostic service provider Synlab to laboratory operator Labcorp , a government document sent to parliament showed.
- 11/20/2024
|
Labcorp CFO Glenn Eisenberg Announces Plans to Retire
- Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C. , Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer.
- 11/19/2024
|
Is Labcorp Stock a Good Pick for Your Portfolio Right Now?
- Investors are increasingly optimistic about LH due to its partnerships and operational discipline.
- 11/15/2024
|
Labcorp Adds New Capabilities to Global Trial Connect: Stock to Gain?
- LH launches new enhancements to Global Trial Connect to streamline site workflow.
- 11/13/2024
|
Labcorp Holdings Inc. (LH) Q3 2024 Earnings Call Transcript
- Labcorp Holdings Inc. (NYSE:LH ) Q3 2024 Earnings Conference Call October 24, 2024 9:00 AM ET Company Participants Christin O'Donnell – Vice President-Investor Relations Adam Schechter – Chairman and Chief Executive Officer Glenn Eisenberg – Executive Vice President and Chief Financial Officer Conference Call Participants Ann Hynes – Mizuho Lisa Gill – JPMorgan Michael Cherny – Leerink Partners Patrick Donnelly – Citi Erin Wright – Morgan Stanley David Westenberg – Piper Sandler Jack Meehan – Nephron Research Pito Chickering – Deutsche Bank Andrew Brackmann – William Blair Kevin Caliendo – UBS Elizabeth Anderson – Evercore ISI Eric Coldwell – Baird Stephanie Davis – Barclays John Kim – Bank of America Operator Good day and thank you for standing by. Welcome to the Q3 2024 Labcorp Holdings Earnings Conference Call.
- 10/24/2024
|
LH Beats on Q3 Earnings, Raises Revenue Guidance Midpoint, Stock Gains
- Labcorp beats on earnings and revenues in the third quarter, entering the fourth half of 2024 with robust momentum.
- 10/24/2024
|
Compared to Estimates, Labcorp (LH) Q3 Earnings: A Look at Key Metrics
- The headline numbers for Labcorp (LH) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 10/24/2024
|
Laboratory Corp Q3 Earnings Beat Street View, Investors Overlook Hurricane Helene Impact
- Thursday, Laboratory Corp LH reported third-quarter 2024 adjusted earnings per share of $3.50, up from $3.38 a year ago, beating the consensus of $3.49.
- 10/24/2024
|
Labcorp (LH) Q3 Earnings and Revenues Surpass Estimates
- Labcorp (LH) came out with quarterly earnings of $3.50 per share, beating the Zacks Consensus Estimate of $3.48 per share. This compares to earnings of $3.38 per share a year ago.
- 10/24/2024
|
Labcorp beats quarterly estimates on diagnostic test demand
- Laboratory operator Labcorp on Thursday beat Wall Street estimates for third-quarter profit and revenue, helped by demand for diagnostic tests.
- 10/24/2024
|
Labcorp Announces 2024 Third Quarter Results
- Updates Full-Year Guidance Results from Continuing Operations for third quarter 2024 versus last year: Revenue: $3.28 billion versus $3.06 billion Diluted EPS: $2.00 versus $2.11 Adjusted EPS: $3.50 versus $3.38 Free Cash Flow: $162 million versus $171 million Updated Full-Year 2024 Guidance: Revenue range of 6.6% to 7.3%; midpoint unchanged Adjusted EPS range of $14.30 to $14.70; midpoint down $0.10, due to the negative impact from weather of approximately $0.15 Free Cash Flow of $850 million to $980 million Announced three new acquisitions/lab management agreements, and closed two acquisitions during the quarter that support growth initiatives BURLINGTON, N.C. , Oct. 24, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the third quarter ended September 30, 2024 and updated full-year guidance.
- 10/24/2024
|
Seeking Clues to Labcorp (LH) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
- Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Labcorp (LH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
- 10/21/2024
|
Labcorp (LH) Reports Next Week: Wall Street Expects Earnings Growth
- Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/17/2024
|
NOWDiagnostics and Labcorp Collaborate to Expand Access to the Only FDA-Marketing Authorized Over-the-Counter Syphilis Test in the U.S.
- SPRINGDALE, Ark.--(BUSINESS WIRE)--NOWDiagnostics, Inc. (NOWDx), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostic tests, today announced that Labcorp, a global leader of innovative and comprehensive laboratory services, will be the exclusive U.S. distributor of its First To Know® Syphilis Test in professional and healthcare settings. Through Labcorp's extensive distribution network and trusted presence in clinical settings, this collaboration will expand access to the sy.
- 10/16/2024
|
Labcorp's Q3 Earnings Looms: Here's What to Expect From the Stock
- LH is expected to perform strongly in both of its segments and will also likely advance in its strategic priorities.
- 10/14/2024
|
Labcorp Expands Sexually Transmitted Infection (STI) Test Offerings with Rapid Syphilis Test
- Labcorp to serve as the exclusive NOWDiagnostics (NOWDx) distributor for clinical testing in the U.S., offering First to Know® Syphilis Test nationwide BURLINGTON, N.C. , Oct 10, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it has expanded its portfolio of sexually transmitted infection (STI) testing options to include the First to Know® Syphilis Test, the first over-the-counter blood test granted market authorization by the U.S. Food & Drug Administration (FDA) that can be performed by both physicians and patients.
- 10/10/2024
|
Labcorp Declares Quarterly Dividend
- BURLINGTON, N.C. , Oct. 10, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock.
- 10/10/2024
|
Labcorp Stock Gains From Biopharma Business Amid FX Woe
- LH is well-placed for long-term success in Cell & Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business.
- 10/07/2024
|
Should You Continue to Retain LH Stock in Your Portfolio?
- Labcorp's expanding testing solutions in high-growth areas, partnerships and focus on operational efficiency instill optimism.
- 09/25/2024
|
Labcorp to Announce Third Quarter Financial Results on October 24, 2024
- BURLINGTON, N.C. , Sept. 24, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the third quarter of 2024 before the market opens on Thursday, October 24, 2024.
- 09/24/2024
|
LH Stock Likely to Gain From the Molecular Bioanalytical Lab Expansion
- Labcorp expands the molecular bioanalytical laboratory in Greenfield, IN.
- 09/24/2024
|
Ovia Health Expands Women's Health Offerings with Comprehensive Postpartum Experience
- New solution is the first holistic program available in a digital app to help women manage the postpartum period BOSTON , Sept. 18, 2024 /PRNewswire/ -- Ovia Health by Labcorp (Ovia) today announced the expansion of its women's health solutions to include a personalized, comprehensive Postpartum Experience – a 12-month program designed to help women manage multiple aspects of the postpartum period through personalized recovery modes, symptom tracking and alerts, and mental health support.
- 09/18/2024
|
Labcorp Stock Gains From Its Latest Acquisition of BioReference Health
- LH completes the acquisition of BioReference Health, a wholly-owned subsidiary of OPKO Health. The acquisition includes BioReference Health's laboratory testing businesses.
- 09/17/2024
|
LABCORP PRICES $650,000,000 IN 4.350% SENIOR NOTES DUE 2030, $500,000,000 IN 4.550% SENIOR NOTES DUE 2032 AND $850,000,000 IN 4.800% SENIOR NOTES DUE 2034
- BURLINGTON, N.C. , Sept. 16, 2024 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH) (Labcorp) announced today that its wholly owned subsidiary, Laboratory Corporation of America Holdings (LCAH), has priced its offering of $2,000,000,000 in senior notes (the Offering).
- 09/16/2024
|
Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health
- Enhances Labcorp's laboratory services network and expands access to its clinical services BURLINGTON, N.C. and MIAMI , Sept.
- 09/16/2024
|
Labcorp Stock Gains From Market Expansion Efforts Amid Macro Woes
- LH is well-placed for long-term success in Cell & Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business.
- 09/12/2024
|
LH Stock Expected to Gain From the Ballad Health Acquisition Deal
- Labcorp has reached an agreement to purchase select outreach laboratory services from Ballad Health.
- 09/11/2024
|
Labcorp to Speak at the Baird 2024 Global Healthcare Conference
- BURLINGTON, N.C. , Sept. 3, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team will participate in a presentation at the Baird 2024 Global Healthcare Conference on Tuesday, September 10, at 3:10 p.m.
- 09/03/2024
|
Labcorp says it could ramp up mpox testing capacity
- Diagnostics firm Labcorp said it is processing approximately 500 mpox tests a month but have the capacity to process approximately 25,000 per month.
- 08/26/2024
|
Should You Hold Labcorp (LH) Stock in Your Portfolio Now?
- Labcorp's (LH) slew of partnerships and acquisitions and robust efforts in high-growth areas bode well.
- 08/22/2024
|
Labcorp (LH) Gains From New Collaborations Amid FX Issues
- Labcorp's (LH) Biopharma Laboratory Services business is benefiting from collaborations with leading pharmaceutical and biotechnology companies.
- 08/14/2024
|
Labcorp Finalizes Acquisition of Select Assets of Invitae
- Extends Labcorp's leadership in genetic testing solutions for oncology and select rare diseases BURLINGTON, N.C. , Aug. 5, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the completion of its acquisition of select assets of Invitae (OTC:NVTAQ), a leading medical genetics company.
- 08/05/2024
|
LabCorp Analysts Boost Their Forecasts After Better-Than-Expected Earnings
- Labcorp Holdings Inc LH reported better-than-expected second-quarter financial results and raised its FY24 revenue guidance above estimates on Thursday.
- 08/02/2024
|
Labcorp Receives FDA De Novo Marketing Authorization for PGDx elio™ plasma focus Dx
- PGDx elio™ plasma focus Dx is the industry's first and only kitted, pan-solid tumor liquid biopsy test that enables tumor mutation profiling – all from a simple blood draw BURLINGTON, N.C., Aug. 2, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it has received De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) for PGDx elio™ plasma focus Dx – the industry's first and only kitted, pan-solid tumor liquid biopsy test.
- 08/02/2024
|
Labcorp (LH) Q2 Earnings Surpass Estimates (revised)
- Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.
- 08/01/2024
|
LabCorp's Stock Soars After Q2 Performance, Analyst Highlights Strong Position In Healthcare Sector
- Thursday, Laboratory Corp A reported second-quarter 2024 adjusted EPS of $3.94, up from $3.42 a year ago, beating the consensus of $3.78.
- 08/01/2024
|
Labcorp (LH) Q2 Earnings Surpass Estimates, Margins Increase
- Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.
- 08/01/2024
|
Compared to Estimates, Labcorp (LH) Q2 Earnings: A Look at Key Metrics
- The headline numbers for Labcorp (LH) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 08/01/2024
|
Labcorp (LH) Beats Q2 Earnings and Revenue Estimates
- Labcorp (LH) came out with quarterly earnings of $3.94 per share, beating the Zacks Consensus Estimate of $3.78 per share. This compares to earnings of $3.42 per share a year ago.
- 08/01/2024
|
Labcorp beats Q2 profit and revenue estimates on demand for health tests
- Labcorp beat Wall Street expectations for second-quarter profit and revenue on Thursday on strong demand for its diagnostic tests, and raised its sales growth forecast for the year.
- 08/01/2024
|
Labcorp Announces 2024 Second Quarter Results
- Updates Full-Year Guidance Results from Continuing Operations for second quarter 2024 versus last year: Revenue: $3.22 billion versus $3.03 billion Diluted EPS: $2.43 versus $1.74 Adjusted EPS: $3.94 versus $3.42 Free Cash Flow: $432.9 million versus $58.2 million Updated Full-Year 2024 Guidance: Revenue range of 6.4% to 7.5%, includes Invitae impact of ~1.0% Adjusted EPS range of $14.30 to $14.90, includes Invitae dilution of ~$0.40 Free Cash Flow of $0.85 billion to $1.00 billion, includes Invitae cash usage of ~$150 million Share repurchase authorization increased by $1.0 billion to $1.4 billion Launched important new tests in specialty testing areas Introduced Labcorp Global Trial Connect, a suite of central laboratory solutions aimed to accelerate clinical trials BURLINGTON, N.C. , Aug. 1, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the second quarter ended June 30, 2024 and updated full-year guidance.
- 08/01/2024
|
What's in Store for These 4 MedTech Stocks in Q2 Earnings?
- Here is a sneak peek into how four MedTech companies, LH, BIO, TFX and BRKR, are expected to fare in their second-quarter results, slated to be released tomorrow.
- 07/31/2024
|
Labcorp Expands Collaboration with Ultima Genomics to Advance Whole Genome Sequencing Applications and Oncology Testing Capabilities
- BURLINGTON, N.C., and FREMONT, Calif.
- 07/30/2024
|
Labcorp (LH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/25/2024
|
Labcorp Declares Quarterly Dividend
- BURLINGTON, N.C., July 25, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock.
- 07/25/2024
|
Here's How Labcorp (LH) is Placed Ahead of Q2 Earnings Release
- Labcorp's (LH) second-quarter 2024 performance is expected to reflect the robust execution of strategic priorities and solid business performances.
- 07/22/2024
|
Here's Why Labcorp (LH) is a Strong Value Stock
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 07/09/2024
|
Is It the Right Time to Hold Labcorp (LH) in Your Portfolio?
- Labcorp's (LH) concentrated development in high-growth areas and strategic partnerships appear encouraging.
- 07/02/2024
|
Labcorp to Announce Second Quarter Financial Results on August 1, 2024
- BURLINGTON, N.C. , July 1, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2024 before the market opens on Thursday, August 1, 2024.
- 07/01/2024
|
Labcorp Launches Global Trial Connect to Accelerate Clinical Trials
- Suite of digital and data solutions designed to improve clinical trial efficiency, reduce data delays and simplify investigator site workflows BURLINGTON, N.C. , June 17, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp Global Trial Connect, a suite of central laboratory solutions aimed at increasing the speed of clinical trials where the heart of clinical research is conducted – investigator sites.
- 06/17/2024
|
Labcorp Announces New Strategic Service Offerings within Precision Oncology Portfolio
- Labcorp® Tissue Complete, a comprehensive genomic profiling service, now available in Geneva and Shanghai to support global clinical trials Company expands leadership in liquid biopsy comprehensive genomic profiling for solid tumors with the integration of OmniSeq® INSIGHT circulating tumor DNA BURLINGTON, N.C. , June 3, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced new strategic service offerings within its precision oncology portfolio.
- 06/03/2024
|
Labcorp to Present Multiple Abstracts across Precision Oncology at the 2024 ASCO Annual Meeting
- Abstracts offer insights into precision oncology diagnostics for triple-negative breast cancer, liquid biopsy and machine learning for tumor profiling BURLINGTON, N.C. , May 30, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will present several abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (May 31 – June 4, 2024).
- 05/30/2024
|
Labcorp to Speak at the 44th Annual William Blair Growth Stock Conference
- BURLINGTON, N.C., May 28, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team will participate in a presentation at the 44th Annual William Blair Growth Stock Conference on Tuesday, June 4 at 2:00 p.m.
- 05/28/2024
|
Why Labcorp (LH) is a Top Value Stock for the Long-Term
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 05/21/2024
|
Foundations Investment Advisors LLC Buys Shares of 1,214 Laboratory Co. of America Holdings (NYSE:LH)
- Foundations Investment Advisors LLC bought a new position in shares of Laboratory Co. of America Holdings (NYSE:LH – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 1,214 shares of the medical research company’s stock, valued at approximately $272,000. Other hedge funds have also recently bought and sold shares of the company. Provence Wealth Management Group purchased a new stake in shares of Laboratory Co. of America during the third quarter worth $29,000. Mendota Financial Group LLC acquired a new stake in Laboratory Co. of America in the 4th quarter valued at about $29,000. Bruce G. Allen Investments LLC acquired a new position in shares of Laboratory Co. of America during the fourth quarter worth about $60,000. Disciplined Equity Management Inc. purchased a new stake in shares of Laboratory Co. of America during the fourth quarter worth approximately $68,000. Finally, Oakworth Capital Inc. raised its holdings in Laboratory Co. of America by 48.1% in the fourth quarter. Oakworth Capital Inc. now owns 308 shares of the medical research company’s stock valued at $70,000 after acquiring an additional 100 shares in the last quarter. Institutional investors and hedge funds own 95.94% of the company’s stock. Wall Street Analysts Forecast Growth LH has been the topic of several recent analyst reports. Argus raised Laboratory Co. of America from a “hold” rating to a “buy” rating and set a $250.00 target price on the stock in a report on Monday, March 25th. TheStreet lowered Laboratory Co. of America from a “b-” rating to a “c+” rating in a research report on Thursday, February 15th. Evercore ISI started coverage on Laboratory Co. of America in a report on Friday, February 9th. They issued an “in-line” rating and a $240.00 price target for the company. Barclays cut their price objective on shares of Laboratory Co. of America from $234.00 to $213.00 and set an “equal weight” rating on the stock in a report on Friday, April 26th. Finally, Robert W. Baird lowered their target price on shares of Laboratory Co. of America from $255.00 to $244.00 and set an “outperform” rating for the company in a report on Friday, April 26th. Four equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $243.14. Read Our Latest Research Report on LH Laboratory Co. of America Stock Down 1.2 % Shares of NYSE:LH opened at $210.59 on Monday. The company has a market cap of $17.75 billion, a price-to-earnings ratio of 42.37, a PEG ratio of 1.58 and a beta of 1.02. Laboratory Co. of America Holdings has a fifty-two week low of $174.20 and a fifty-two week high of $234.09. The firm’s 50-day simple moving average is $208.28 and its 200-day simple moving average is $215.41. The company has a quick ratio of 0.76, a current ratio of 0.88 and a debt-to-equity ratio of 0.39. Laboratory Co. of America (NYSE:LH – Get Free Report) last released its earnings results on Thursday, April 25th. The medical research company reported $3.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.48 by $0.20. The company had revenue of $3.18 billion for the quarter, compared to analysts’ expectations of $3.12 billion. Laboratory Co. of America had a return on equity of 14.68% and a net margin of 3.52%. The firm’s quarterly revenue was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.82 EPS. As a group, equities research analysts predict that Laboratory Co. of America Holdings will post 14.87 earnings per share for the current year. Laboratory Co. of America Announces Dividend The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 12th. Stockholders of record on Tuesday, May 28th will be paid a dividend of $0.72 per share. The ex-dividend date is Friday, May 24th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.37%. Laboratory Co. of America’s dividend payout ratio (DPR) is presently 57.95%. Insider Activity In other Laboratory Co. of America news, EVP Jonathan P. Divincenzo sold 500 shares of the company’s stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $215.49, for a total transaction of $107,745.00. Following the transaction, the executive vice president now directly owns 3,401 shares in the company, valued at $732,881.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, EVP Jonathan P. Divincenzo sold 500 shares of the business’s stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $215.49, for a total value of $107,745.00. Following the sale, the executive vice president now directly owns 3,401 shares in the company, valued at approximately $732,881.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CAO Peter J. Wilkinson sold 2,439 shares of the firm’s stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $204.33, for a total transaction of $498,360.87. Following the transaction, the chief accounting officer now owns 2,087 shares of the company’s stock, valued at $426,436.71. The disclosure for this sale can be found here. Insiders sold 58,748 shares of company stock worth $12,670,956 in the last 90 days. 0.85% of the stock is currently owned by corporate insiders. Laboratory Co. of America Company Profile (Free Report) Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS). See Also Five stocks we like better than Laboratory Co. of America 3 Natural Gas Stocks That Offer Great Dividend Yields Canada Goose Flies Higher Driven By DTC Growth Dividend Screener: How to Evaluate Dividend Stocks Before Buying CVS Health Stock Has a Silver Lining Called Value Conference Calls and Individual Investors Magnificent 7 Still Magnificent as the Halfway Mark Approaches?
- 05/20/2024
|
Labcorp (LH) to Assess Preeclampsia Risk With New Test
- Labcorp's (LH) new first-trimester test is the latest addition to its dedication to improving women's health.
- 05/16/2024
|
Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk during Pregnancy
- Labcorp is now the only lab that can detect preeclampsia risk across all pregnancy trimesters BURLINGTON, N.C. , May 15, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of its first trimester preeclampsia screening test to be performed between 11 and 14 weeks gestation to determine the risk of developing preeclampsia before 34 weeks of pregnancy.
- 05/15/2024
|
Here's Why Investors Should Retain Labcorp (LH) Stock for Now
- Investors are optimistic about Labcorp (LH), led by strategic acquisitions and strong expansion in the Biopharma Laboratory.
- 05/09/2024
|
Labcorp to Webcast Its Annual Meeting of Shareholders
- BURLINGTON, N.C. , May 8, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that its Annual Meeting of Shareholders will be webcast live on May 14 at 9:00 a.m.
- 05/08/2024
|
Invitae Receives Court Approval for Sale to Labcorp
- Acquisition advances Labcorp's specialty testing strategy in key areas such as oncology and rare diseases Key milestone reached in Invitae's Chapter 11 process BURLINGTON, N.C. and SAN FRANCISCO , May 7, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and Invitae (OTC:NVTAQ), a leading medical genetics company, announced today that the United States Bankruptcy Court has approved the previously announced bid by Labcorp to acquire assets of Invitae.
- 05/07/2024
|
FDA Approves ColoSense™ – Geneoscopy's Noninvasive Multi-target Stool RNA (mt-sRNA) Colorectal Cancer Screening Test
- ST. LOUIS--(BUSINESS WIRE)--Geneoscopy, Inc. announced that the U.S. Food and Drug Administration (FDA) approved its noninvasive colorectal cancer screening test, ColoSense.
- 05/06/2024
|
FDA brings lab tests under federal oversight in bid to improve accuracy and safety
- WASHINGTON — Makers of medical tests that have long escaped government oversight will have about four years to show that their new offerings deliver accurate results, under a government rule vigorously opposed by the testing industry.
- 04/29/2024
|
Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B
- Assay expands company's leadership in precision medicine and cell and gene therapy BURLINGTON, N.C. , April 29, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the U.S. Food and Drug Administration (FDA) has approved its nAbCyte™ Anti-AAVRh74var HB-FE Assay, a companion diagnostic (CDx) to determine patient eligibility for treatment with BEQVEZ™ (fidanacogene elaparvovec-dzkt), Pfizer's recently FDA-approved hemophilia B gene therapy.
- 04/29/2024
|
3 Medical Products Stocks Set to Beat This Earnings Season
- Here are three stocks, TXG, CAH and HOLX, which are expected to beat earnings estimates in the ongoing reporting cycle.
- 04/26/2024
|
Labcorp (LH) Tops Q1 Earnings Estimates, Raises 2024 EPS View
- Labcorp (LH) sets a strong foundation for the year ahead with its impressive performance in the first quarter of 2024.
- 04/25/2024
|
Compared to Estimates, Labcorp (LH) Q1 Earnings: A Look at Key Metrics
- Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 04/25/2024
|
Labcorp beats quarterly estimates on strong testing demand
- Labcorp beat Wall Street expectations for first-quarter profit on Thursday, as growing demand for specialty tests boosted sales at its diagnostics business.
- 04/25/2024
|
Labcorp Announces 2024 First Quarter Results
- Updates Full-Year Guidance Results from Continuing Operations for first quarter 2024 versus last year: Revenue: $3.18 billion versus $3.04 billion or up 4.6% | Base Business grew 6.7% Diluted EPS: $2.69 versus $2.34 Adjusted EPS: $3.68 versus $3.46 Full-Year 2024 Guidance: Raised midpoint and narrowed range of adjusted EPS to $14.45 to $15.35; Free Cash Flow remains $1.00 billion to $1.15 billion Year to date announced/completed five acquisitions that support our strategy Significantly expanded our test menu in key therapeutic areas BURLINGTON, N.C. , April 25, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the first quarter ended March 31, 2024 and updated full-year guidance.
- 04/25/2024
|
Clinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 mln
- Laboratory service provider Labcorp said on Wednesday it will acquire Softbank-backed Invitae Corp's assets auctioned through a voluntary bankruptcy protection process, a few months after the genetic test maker filed for bankruptcy.
- 04/24/2024
|
Labcorp Announces Winning Bid for Select Assets of Invitae
- Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 BURLINGTON, N.C. , April 24, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company.
- 04/24/2024
|
Invitae Enters into Agreement with Labcorp for Sale of Business
- – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantially All of the Company's Assets, Ensuring Business Continuity for Customers, Partners and Employees – SAN FRANCISCO , April 24, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, announced that Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, has been selected as the winning bidder in the Company's auction in its sale process under Section 363 of the U.S. Bankruptcy Code. Labcorp will acquire substantially all of the Company's assets on a going concern basis for $239 million in cash consideration, plus other non-cash consideration.
- 04/24/2024
|
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?
- Here is a sneak peek into how the three major MedTech stocks, LH, EW and RMD, are expected to fare in their quarterly results slated to be released tomorrow.
- 04/24/2024
|
Exploring Analyst Estimates for Labcorp (LH) Q1 Earnings, Beyond Revenue and EPS
- Get a deeper insight into the potential performance of Labcorp (LH) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
- 04/22/2024
|
5 Large-Cap Medical Stocks to Buy Ahead of Q1 Earnings
- We have narrowed our search to five S&P 500 medical stocks that are poised to beat on first-quarter earnings results.These are: HCA, UHS, LH, EW, PODD.
- 04/19/2024
|
Labcorp (LH) Expected to Beat Earnings Estimates: Should You Buy? (Revised)
- Labcorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/19/2024
|
Why Labcorp (LH) Could Beat Earnings Estimates Again
- Labcorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 04/18/2024
|
LH vs. COO: Which Stock Should Value Investors Buy Now?
- Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Labcorp (LH) and The Cooper Companies (COO). But which of these two stocks presents investors with the better value opportunity right now?
- 04/17/2024
|
Should Value Investors Buy Labcorp (LH) Stock?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 04/17/2024
|
Labcorp's (LH) At-Home Mpox Testing Kit Gets the FDA's EUA Nod
- Labcorp (LH) receives the FDA's Emergency Use Authorization for the Mpox PCR Test Home Collection Kit.
- 04/12/2024
|
Labcorp's (LH) Strategic Alliances Aid Amid Macroeconomic Woes
- Labcorp (LH) is investing in innovation and technology that supports diagnostic and drug development testing for various diseases such as cancer and Alzheimer's.
- 04/09/2024
|
Labcorp (LH) Extends MRD Clinical Research With New Launch
- Labcorp (LH) Plasma Detect MRD solution advances its leadership in precision oncology across the solid tumor oncology care continuum.
- 04/08/2024
|
Here's Why Investors Should Retain Labcorp (LH) Stock for Now
- Investors are optimistic about Labcorp (LH) on the continued strength of Central Labs, which is driving the success of the biopharma segment.
- 04/02/2024
|
Labcorp (LH) to Boost Clinical Diagnostics With New Deal
- The recent deal will augment Labcorp's (LH) laboratory services network and expand access to the company's high-quality clinical laboratory services.
- 04/01/2024
|
Labcorp (LH) Boost Diagnostics Suite With New Biomarker Test
- Labcorp's (LH) pTau217 test is a pivotal blood biomarker intended to aid in the diagnosis of Alzheimer's disease.
- 03/25/2024
|
Labcorp (LH) Expands Strategic Alliances, Test Sales Fall
- Labcorp (LH) continues to progress in terms of integrating hospital partnerships and acquisitions.
- 03/15/2024
|
LH or COO: Which Is the Better Value Stock Right Now?
- Investors interested in Medical - Dental Supplies stocks are likely familiar with Labcorp (LH) and The Cooper Companies (COO). But which of these two stocks offers value investors a better bang for their buck right now?
- 03/12/2024
|
Are Investors Undervaluing Labcorp (LH) Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 03/12/2024
|
Labcorp (LH) Introduces Weight Loss Management Portfolio
- Labcorp's (LH) Weight Loss Management service includes proven tests from its extensive menu and simplifies the procedure for both physicians and patients.
- 03/08/2024
|
Here's Why Investors Should Hold Labcorp (LH) Stock for Now
- Targeted development in high-growth areas and strategic partnerships bode well for Labcorp (LH).
- 02/26/2024
|
Is Labcorp (LH) Stock Undervalued Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 02/23/2024
|
Labcorp (LH) Moves to Buy: Rationale Behind the Upgrade
- Labcorp (LH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 02/21/2024
|
LH vs. COO: Which Stock Is the Better Value Option?
- Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Labcorp (LH) or The Cooper Companies (COO). But which of these two companies is the best option for those looking for undervalued stocks?
- 02/21/2024
|
Compared to Estimates, Labcorp (LH) Q4 Earnings: A Look at Key Metrics (Revised)
- Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 02/19/2024
|
Labcorp (LH) Surpasses Q4 Earnings and Revenue Estimates (Revised)
- Labcorp (LH) came out with quarterly earnings of $3.30 per share, beating the Zacks Consensus Estimate of $3.29 per share. This compares to earnings of $3.05 per share a year ago.
- 02/16/2024
|
Labcorp (LH) Surpasses Q4 Earnings and Revenue Estimates (Revised)
- Labcorp (LH) came out with quarterly earnings of $3.30 per share, beating the Zacks Consensus Estimate of $3.29 per share. This compares to earnings of $3.05 per share a year ago.
- 02/16/2024
|
Labcorp (LH) Q4 Earnings and Revenues Beat, Margins Fall
- Strength in Diagnostics Laboratories and Biopharma Laboratory Services businesses contributes to Labcorp's (LH) Q4 performance.
- 02/15/2024
|
Laboratory Corporation of America Holdings (LH) Q4 2023 Earnings Conference Call Transcript
- Laboratory Corporation of America Holdings (LH) Q4 2023 Earnings Conference Call Transcript
- 02/15/2024
|
Compared to Estimates, Labcorp (LH) Q4 Earnings: A Look at Key Metrics
- Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 02/15/2024
|
Labcorp (LH) Surpasses Q4 Earnings and Revenue Estimates
- Labcorp (LH) came out with quarterly earnings of $3.30 per share, beating the Zacks Consensus Estimate of $3.29 per share. This compares to earnings of $4.14 per share a year ago.
- 02/15/2024
|
Analysts Estimate Labcorp (LH) to Report a Decline in Earnings: What to Look Out for
- Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/08/2024
|
LabCorp (LH) Unveils Test for Preeclampsia in Pregnant Women
- LabCorp (LH) test System, which is available through clinicians, is the first FDA-cleared biomarker test to aid in the risk assessment of progression to severe preeclampsia.
- 02/01/2024
|
Oncology Space Gains Momentum: 3 Stocks in Focus
- Stocks such as EXAS, DGX and LH are likely to potentially continue the momentum in the oncology field.
- 01/23/2024
|
LabCorp (LH) to Expand Clinical Trails Access With New Pact
- LabCorp (LH) and Hawthorne Effect hope to enhance decentralized clinical trials by merging existing services and developing fresh, unique service offers.
- 01/11/2024
|
Here's Why Investors Should Retain Labcorp (LH) Stock for Now
- Investors are increasingly optimistic about Labcorp (LH) due to development in targeted high-growth areas.
- 11/27/2023
|
Labcorp (LH) Closes the Legacy Health Asset Acquisition Deal
- Labcorp (LH) finalizes the comprehensive laboratory relationship with Legacy Health.
- 11/24/2023
|
Labcorp (LH) Q3 Earnings and Revenues Beat, Margins Fall
- Labcorp (LH) delivers a strong performance in the third quarter of 2023 across the Diagnostics Laboratories and Biopharma Laboratory Services businesses.
- 10/26/2023
|
Here's What Key Metrics Tell Us About Labcorp (LH) Q3 Earnings
- Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 10/26/2023
|
Labcorp (LH) Surpasses Q3 Earnings and Revenue Estimates
- Labcorp (LH) came out with quarterly earnings of $3.38 per share, beating the Zacks Consensus Estimate of $3.37 per share. This compares to earnings of $4.68 per share a year ago.
- 10/26/2023
|
Labcorp beats quarterly profit estimates on strength in routine testing segment
- Laboratory Corporation of America topped Wall Street expectations for quarterly adjusted profit on Thursday, as strength in its routine diagnostics business more than offset weak COVID test sales.
- 10/26/2023
|
Labcorp (LH) Launches Biomarker Test for Alzheimer's Disease
- Labcorp's (LH) new test, ATN Profile, is likely to accelerate the path to the diagnosis of Alzheimer's disease.
- 10/13/2023
|
Labcorp launches 3-part blood test for Alzheimer's
- Labcorp on Wednesday began marketing to U.S. physicians the first test for a trio of blood biomarkers it says can detect the hallmarks of Alzheimer's, accelerating diagnosis of the brain-wasting disease and potentially helping patients access treatment.
- 10/11/2023
|
Labcorp to Announce Third Quarter Financial Results on October 26, 2023
- BURLINGTON, N.C. , Sept. 29, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the third quarter of 2023 before the market opens on Thursday, October 26, 2023.
- 09/29/2023
|
Here's Why Investors Should Retain Labcorp (LH) Stock for Now
- Investors are increasingly optimistic about Labcorp (LH) due to its progress in hospital partnerships.
- 09/28/2023
|
LabCorp (LH) Suffers From Lower COVID Test Sales, Macro Woes
- Labcorp's (LH) Early Development Research Laboratories business continues to be constrained by NHP-related supply-chain issues.
- 08/28/2023
|
The 7 Most Undervalued Value Stocks to Buy Now: August 2023
- While the glitz and glamour of the hottest technology firms organically command our attention, investors should earmark some time for researching value stocks to buy. Fundamentally, these under-the-radar ideas offer the potential for significant returns.
- 08/17/2023
|
3 MedTech Stocks Likely to Top Estimates This Earnings Season
- MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EYE, CAH and HSIC are poised ahead of their earnings releases.
- 08/03/2023
|
LabCorp (LH) Q2 Earnings Miss Estimates, Margins Decline
- A rise in organic revenues, acquisitions, net of divestitures and foreign currency translation drive LabCorp's (LH) Q2 revenues.
- 07/27/2023
|
Laboratory Corporation of America Holdings (LH) Q2 2023 Earnings Call Transcript
- Laboratory Corporation of America Holdings (NYSE:LH ) Q2 2023 Earnings Conference Call July 27, 2023 9:00 AM ET Company Participants Chas Cook – Vice President-Investor Relations Adam Schechter – Chairman and Chief Executive Officer Glenn Eisenberg – Executive Vice President and Chief Financial Officer Conference Call Participants Jack Meehan – Nephron Research Lisa Gill – JPMorgan A.J. Rice – Credit Suisse Eric Coldwell – Baird Brian Tanquilut – Jefferies Kevin Caliendo – UBS Patrick Donnelly – Citi Kieran Ryan – Deutsche Bank Tim Daley – Wells Fargo Securities Operator Good day.
- 07/27/2023
|
Watch these stocks as they approach bullish 'golden cross' pattern, says technician Carter Worth
- Carter Worth, Worth Charting CEO, joins 'Power Lunch' to give his read on the technicals, looking at stocks on the verge of a breakout.
- 07/19/2023
|
Laboratory Corporation: Trying To Create Value By Spinning Out Fortrea
- Laboratory Corporation of America Holdings shares have been hurt by the boom-bust cycle induced by the pandemic. Tough comparables should run off in the coming quarters, as the company is simplifying the business with the Fortrea spinoff. Overall valuations look quite reasonable, amidst modest leverage ratios, which makes me upbeat with earnings growth set to return in the coming quarters.
- 07/05/2023
|
LabCorp (LH) Partners With Forge Biologics for Gene Therapies
- LabCorp's (LH) latest partnership will significantly assist patients gain access to cutting-edge, potentially life-saving medication.
- 07/05/2023
|
Labcorp (LH) Announces Completion of the Fortrea Spin-off
- Labcorp (LH) completes the planned spin-off of Fortrea to operate as an independent clinical development business.
- 07/04/2023
|
Why Shares of Labcorp Dropped Monday
- While the spinoff deal is positive for Labcorp, investors used the opportunity to sell on the news. Labcorp will do a $1 billion stock repurchase program and pay down debt.
- 07/03/2023
|
Labcorp spins off Fortrea contract research organization with stock debut on the Nasdaq
- Labcorp LH, +0.35% said Monday it completed the spin-off of Fortrea FTREV, -3.98% as an independent contract research organization (CRO) that specializes in Phase I-IV clinical trial management, patient access and technology solutions to pharmaceutical and biotechnology organizations around the world. Fortrea will begin trading on the Nasdaq starting on Monday under the symbol “FTRE”.
- 07/03/2023
|
Labcorp to Announce Second Quarter Financial Results on July 27, 2023
- BURLINGTON, N.C. , June 29, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the second quarter of 2023 before the market opens on Thursday, July 27, 2023.
- 06/29/2023
|
Laboratory Corporation: Predictability Of Cash Flows Less Visible
- Laboratory Corporation has visible headwinds to growth ahead. The company's return on capital employed has lagged behind the required rate of return in the last two periods. Net-net, reiterate that LH stock is a hold, valuation of $221.
- 06/20/2023
|
LabCorp (LH) Gives Update as Fortrea Spinoff Nears Closure
- Fortrea is set to comprise Labcorp's (LH) Clinical Development and Commercialization Services businesses.
- 06/12/2023
|
LabCorp (LH) Provides Update on Planned Spinoff of Fortrea
- After separation from LabCorp (LH), Fortrea is set to operate as a global contract research organization that offers comprehensive drug and medical device development services.
- 06/07/2023
|
LabCorp (LH) Expands Precision Oncology With Biopsy Test
- The addition of Labcorp Plasma Focus marks a pivotal step in the expansion of LabCorp's (LH) suite of precision oncology tests.
- 06/01/2023
|
3 No-Brainer Stocks to Buy in a Correction
- NextEra Energy is a utility powerhouse, positioned to keep growing. Laboratory Corp. of America is a leader in diagnostic testing.
- 05/26/2023
|
Why Is LabCorp (LH) Down 2.7% Since Last Earnings Report?
- LabCorp (LH) reported earnings 30 days ago. What's next for the stock?
- 05/25/2023
|
LabCorp (LH) Expands Laboratory Relationship With New Pact
- LabCorp's (LH) recent partnership will expand healthcare access, offer advanced diagnostic tools and guarantee that both patients and doctors can afford the treatments they get.
- 05/17/2023
|
Here's Why Investors Should Retain LabCorp (LH) Stock for Now
- Investors are optimistic about LabCorp (LH) on strategic partnerships and upbeat guidance.
- 05/16/2023
|
LabCorp (LH) Base Business Growth Strong, Margin Pressure Stays
- LabCorp (LH) is progressing well with its planned spin-off of the Clinical Development business, which is expected to be completed in mid-2023.
- 05/16/2023
|
Laboratory Corporation of America Holdings (LH) Q1 2023 Earnings Call Transcript
- Laboratory Corporation of America Holdings (LH) Q1 2023 Earnings Call Transcript.
- 04/25/2023
|
LabCorp (LH) Q1 Earnings Miss Estimates, Margins Decline
- The decline in COVID-19 PCR and antibody testing sales, the severe foreign exchange headwind and inflationary pressure hurt LabCorp's (LH) business performance in Q1.
- 04/25/2023
|
LabCorp (LH) Misses Q1 Earnings Estimates
- LabCorp (LH) came out with quarterly earnings of $3.82 per share, missing the Zacks Consensus Estimate of $3.99 per share. This compares to earnings of $6.11 per share a year ago.
- 04/25/2023
|
7 Low-PE Ratio Blue-Chip Stocks Offering Both Quality and Value
- While the concept of acquiring low-PE ratio blue-chip stocks (that is, industry-leading stalwarts that feature low price-earnings ratios relative to their sectors) appeals on paper, investors need to be cautious. You can't just buy companies based on any one single metric.
- 04/19/2023
|
8 Defensive Plays as Healthcare Stocks Stumble
- Healthcare stocks have sputtered this year after performing well in 2022. A Barron's screen has identified stocks that are poised to outperform for the rest of the year.
- 04/19/2023
|
LabCorp (LH) Expands Colon Cancer Test Access With New Pact
- LabCorp's (LH) at-home collection kit will offer patients an additional and easier option to get screened for colon cancer.
- 04/04/2023
|
Labcorp to pay $2.1 million to settle allegations it overbilled Defense Department for genetic tests for military members
- A former Labcorp employee turned whistleblower sued the diagnostic testing company in 2018 on behalf of the federal government under the False Claims Act.
- 03/27/2023
|
Here's Why Investors Should Retain LabCorp (LH) Stock for Now
- Investors are optimistic about LabCorp (LH) backed by strength in its Drug Development business.
- 03/14/2023
|
LabCorp (LH) Focuses on High-Growth Areas Amid Currency Woe
- In its efforts to expand further, LabCorp (LH) is focusing more on high-growth opportunity areas such as neurodegenerative, autoimmune and liver disease as well as cell and gene therapy.
- 03/08/2023
|
Laboratory Corporation of America Holdings (LH) Q4 2022 Earnings Call Transcript
- Laboratory Corporation of America Holdings (NYSE:LH ) Q4 2022 Earnings Conference Call February 16, 2023 9:00 AM ET Company Participants Chas Cook - Vice President of Investor Relations Adam Schechter - President, Chief Executive Officer & Chairman Glenn Eisenberg - Executive Vice President & Chief Financial Officer Conference Call Participants Kevin Caliendo - UBS Jack Meehan - Nephron Research Erin Wright - Morgan Stanley Tim Daley - Wells Fargo Patrick Donnelly - Citi Operator Good day, and thank you for standing by. Welcome to the Q4 and Full Year 2022 Labcorp Conference Call.
- 02/16/2023
|
LabCorp (LH) Q4 Earnings Surpass Estimates, Margins Fall
- The severe foreign exchange headwind, inflationary pressure and the ongoing Ukraine/Russia crisis impact LabCorp's (LH) business performance in Q4.
- 02/16/2023
|
LabCorp reports 20% drop in COVID test sales in Q4
- Shares of Labcorp LH, +1.79% were down about 2.9% in premarket trading on Thursday after the diagnostics company reported lower-than-expected revenue in the fourth quarter of 2022. Labcorp had earnings of $76.4 million, or 86 cents per share, in the fourth quarter, down from $553.6 million, or $5.75 per share, in the same quarter in 2021.
- 02/16/2023
|
Labcorp to spin off its clinical research organization under the name Fortrea
- Labcorp LH, -0.52% said Thursday that it plans to spin off its clinical development business into a publicly traded clinical research organization, or CRO, in mid-2023. The name of the planned spin-off is Fortrea, and it will employ about 19,000 people under CEO Tom Pike.
- 02/09/2023
|
LabCorp's (LH) New Launches, Planned Spinoff to Aid Growth
- In terms of portfolio enhancement, LabCorp (LH) enters into a collaboration with Becton, Dickinson and Company to advance in life-changing treatments for cancer and other diseases.
- 02/06/2023
|
5 Dental Supplies Stocks to Buy Amid Recovering Prospects
- Here, we discuss five stocks from the Dental Supplies industry that are likely to create wealth for investors - MCK, ABC, LH, CAH and MMSI.
- 02/03/2023
|
Are Investors Undervaluing Laboratory Corp. of America (LH) Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 02/01/2023
|
Laboratory Corporation: Plenty Of Growth Runway
- Labcorp is a strong player in the diagnostics space, with a network of 2,000 patient service centers. It has a long growth runway as its efficient scale makes it appealing for hospitals to outsource this essential function.
- 01/19/2023
|
Labcorp to Announce Fourth Quarter and Full Year 2022 Financial Results on February 16, 2023
- BURLINGTON, N.C.--( BUSINESS WIRE )--Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the fourth quarter and full year 2022 before the market opens on Thursday, Feb. 16, 2023. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.
- 01/18/2023
|
Is Laboratory Corp. of America (LH) Stock Undervalued Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 01/16/2023
|
Here's Why Investors Should Retain LabCorp (LH) Stock for Now
- Investors are optimistic about LabCorp (LH), led by strength in its Drug Development business.
- 12/09/2022
|
Laboratory Corporation: Buy Rating Holds Following Solid Mid-Level Growth
- LabCorp continues to rate as a buy following its Q3 numbers, despite a large pullback in Covid-19 revenue. Offsetting the distribution to its top-line, LH continues to compound capital and return on equity in the double digits, with debt flat YoY.
- 11/08/2022
|
Laboratory Corporation of America Holdings (LH) Q3 2022 Earnings Call Transcript
- Laboratory Corporation of America Holdings (NYSE:LH ) Q3 2022 Earnings Conference Call October 27, 2022 9:00 AM ET Company Participants Chas Cook - VP, IR Adam Schechter - President, CEO & Chairman Glenn Eisenberg - CFO & EVP Conference Call Participants Jack Meehan - Nephron Research Erin Wright - Morgan Stanley Patrick Donnelly - Citigroup Eric Coldwell - Robert W. Baird & Co. A.J.
- 10/27/2022
|
LabCorp (LH) Q3 Earnings and Revenues Miss Estimates
- LabCorp (LH) delivered earnings and revenue surprises of -0.64% and 5.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 10/27/2022
|
Labcorp's stock falls 4% after COVID-19 test sales decline in the third quarter
- Shares of Labcorp LH, +0.76% tumbled 4.7% in premarket trading on Thursday after the diagnostics company said revenue in the third quarter of 2022 came in lower than expected as fewer people got PCR or antigen tests for COVID-19. Labcorp had earnings of $352.8 million, or $3.90 per share, in the third quarter of 2022, down from $587.3 million, or $6.05 per share, in the same quarter a year ago.
- 10/27/2022
|
2 Health Care Stocks That Fit Graham's Lost Formula
- U.S. market indexes rose on Thursday morning as investors were encouraged by several key earnings reports and Treasury yields continued to climb.
- 10/20/2022
|
Labcorp CEO Adam Schechter on COVID-19, flu season, home testing advances, health equity, and more
- Labcorp CEO Adam Schechter speaks about various aspects of the heath care industry at Yahoo Finance's All Markets Summit.
- 10/17/2022
|
Labcorp to Announce Third Quarter Financial Results on October 27, 2022
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the third quarter of 2022 before the market opens on Thursday, Oct. 27, 2022. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor R
- 09/27/2022
|
Analysts Totally Blow It On 12 Gutsy Stock Recommendations
- Wall Street analysts follow S&P 500 stocks more closely than almost anyone. But even they get it wrong sometimes, too.
- 09/16/2022
|
LabCorp: Drug Development Segment Spinoff Poised To Generate Significant Value
- LabCorp announced that it is pursuing a tax-free spinoff of its Drug Development segment. The transaction will separate a slower-growing, highly profitable cash cow from a high growth business, allowing investors to realize significant value.
- 08/23/2022
|
Laboratory Corp: The Force Is Strong With This One
- Labcorp is a well-run company that should benefit from long-term secular trends in the healthcare industry. It benefits from its large patient database, which aids its drug development services business for large pharmaceutical companies.
- 08/17/2022
|
10 defensive stocks that can also provide you with growth and dividends over the long term
- The S&P 500 Index has rallied 10% since June 22 from a deep decline, but there are different schools of thought about whether investors are out of the woods yet.
- 08/10/2022
|
These 3 Companies Are Taking on Monkeypox
- A vaccine maker, a therapeutics company, and a medical lab could suit a variety of investor risk profiles.
- 08/04/2022
|
Labcorp To Spin Off Clinical Development Business
- LH, $257.94; Market Capitalization: $23.3 billion), a leading global life sciences company, announced that its Board of Directors authorized a plan to spin-off Clinical Development business into an independent, publicly traded company.
- 08/02/2022
|
Time for a Breath of Sanity
- After a drop of about 20% in the first six months of this year, investors feel nervous even though July has been good.
- 08/01/2022
|
Laboratory Corporation of America Holdings (LH) CEO Adam Schechter on Q2 2022 Results - Earnings Call Transcript
- Laboratory Corporation of America Holdings (NYSE:LH ) Q2 2022 Earnings Conference Call July 28, 2022 9:00 AM ET Company Participants Chas Cook - VP, IR Adam Schechter - President, CEO & Chairman Glenn Eisenberg - CFO & EVP Conference Call Participants Rivka Goldwasser - Morgan Stanley A.J. Rice - Crédit Suisse Taji Phillips - Jefferies Jack Meehan - Nephron Research Eric Coldwell - Robert W.
- 07/28/2022
|
LabCorp (LH) Q2 Earnings Beat Estimates
- LabCorp (LH) delivered earnings and revenue surprises of 6.21% and 3.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 07/28/2022
|
Labcorp to spin off its clinical-development business
- Shares of Labcorp LH, +1.03% gained 4.2% in premarket trading on Thursday after beating earnings expectations for the second quarter and announcing plans to spin off its clinical-development business, which provides contract-research organization services, next year. The company reported earnings of $358.6 million, or $3.87 per share, in the second quarter of 2022, compared with $467.4 million, or $4.76 per share, in the same three months of last year.
- 07/28/2022
|
Labcorp to Announce Second Quarter Financial Results on July 28, 2022
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the second quarter of 2022 before the market opens on Thursday, July 28, 2022. The company will host a conference call and webcast beginning at 9 a.m. EDT that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. Interested parties can access the conference call by
- 07/14/2022
|
LabCorp (LH) Debuts NfL Test for Neuronal Damage Diagnosis
- LabCorp's (LH) widely accessible NfL blood test presents direct evidence of neuronal injury resulting from brain injury or diseases like Alzheimer's, among others.
- 07/14/2022
|
LabCorp's (LH) Base Testing Volume Grows, Costs Rise
- LabCorp's (LH) slew of product launches and collaborations to pursue short- and long-term high-growth opportunities instill optimism.
- 07/08/2022
|
LabCorp (LH) to Offer Monkeypox Test, Double CDC's Capacity
- Labcorp (LH) is set to become the first national laboratory to offer this PCR test, verified for the CDC.
- 07/07/2022
|
LabCorp (LH) to Strengthen Laboratory Footprint in Japan
- LabCorp's (LH) Drug Development arm, in collaboration with BML, will open a 4,000-square meters lab facility in Kawagoe for global clinical trials.
- 07/04/2022
|
5 ‘Strong Buy' BofA Securities Value 10 Stocks With Very Dependable Dividends
- For years, analysts and portfolio managers have anticipated the return of value stocks as the market moved higher.
- 06/28/2022
|
Here's Why Investors Should Retain LabCorp (LH) Stock for Now
- Investors are optimistic about LabCorp's (LH) robust Drug Development business performance and several pandemic-related developments.
- 06/21/2022
|
Quest Diagnostic Stock is Ready to Move Higher
- Medical diagnostic lab company Quest Diagnostic (NYSE: DGX) stock has been performing relatively stronger than the benchmark indices down only (-20%) on the year.
- 06/21/2022
|
Strength Seen in LabCorp (LH): Can Its 3.7% Jump Turn into More Strength?
- LabCorp (LH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 06/20/2022
|
Laboratory Corp: 15% Reward Asymmetry Under-Reflected, Seeking Exit At $280 Per Share
- Laboratory Corporation of America's defensible cash production separates it from peers in the current macro-climate. Shares have traded down in recent times, and we feel the company's bottom line fundamentals are under-appreciated by the market.
- 06/05/2022
|
LabCorp (LH) to Enhance Access to OmniSeq INSIGHT via New Program
- LabCorp's (LH) new sponsored lung cancer program will expand access to comprehensive genomic testing for NSCLC patients to guide informed treatment decisions.
- 06/03/2022
|
Bernard Horn Adds 5 Stocks to Portfolio in 1st Quarter
- Polaris Capital Management leader Bernard Horn (Trades, Portfolio) released his first-quarter portfolio earlier this month.
- 05/25/2022
|
LabCorp (LH) Introduces Latest Assay for Skin Cancer Patients
- LabCorp's (LH) new assay is claimed to have shown a demonstrable clinical advantage in patients suffering from melanoma.
- 05/20/2022
|
LabCorp (LH) Debuts At-home Collection Kit for Diabetes Testing
- LabCorp's (LH) at-home collection kit makes it effortless for consumers to understand their diabetes risk and health status using an innovative and approved collection device.
- 05/17/2022
|
FDA authorizes Labcorp's direct-to-consumer test for RSV, the flu, and COVID-19
- The Food and Drug Administration on Monday authorized a test developed by Laboratory Corporation of America Holdings LH, -0.85% that allows people in the U.S. to self-test for respiratory syncytial virus (RSV), a type of common cold, as well as the flu and COVID-19. The test does not require a prescription.
- 05/16/2022
|
Here's Why You Should Retain LabCorp (LH) Stock for Now
- Investors are optimistic about LabCorp's (LH) better-than-expected earnings and robust segmental performance.
- 05/13/2022
|
12 of Wall Street's Newest Dividend Stocks
- Skyrocketing inflation has spurred demand for investments that can keep pace with rising prices. This includes renewed interest in income-paying investments, including both old and new dividend stocks.
- 05/06/2022
|
Laboratory Corporation of America Holdings (LH) CEO Adam Schechter on Q1 2022 Results - Earnings Call Transcript
- Laboratory Corporation of America Holdings (NYSE:LH ) Q1 2022 Earnings Conference Call April 28, 2022 9:00 AM ET Company Participants Chas Cook - Vice President, Investor Relations Adam Schechter - Chairman and Chief Executive Officer Glenn Eisenberg - Executive Vice President and Chief Financial Officer Conference Call Participants Jack Meehan - Nephron Research Ricky Goldwasser - Morgan Stanley Eric Coldwell - Baird Operator Good day, and thank you for standing by. Welcome to the Labcorp's First Quarter 2022 Earnings Conference Call [Operator Instructions].
- 04/28/2022
|
LabCorp (LH) Q1 Earnings Surpass Estimates, Revenues Miss
- LabCorp (LH) reports better-than-expected earnings for the first quarter, with robust sales within the Drug Development arm driving the top line.
- 04/28/2022
|
LabCorp (LH) Surpasses Q1 Earnings Estimates
- LabCorp (LH) delivered earnings and revenue surprises of 3.91% and 3.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 04/28/2022
|
Medical Products Stocks' Earnings on Apr 28: TMO, BIO & More
- Medical Products companies' results are likely to reflect a rebound in the base business. Let's see how TMO, BIO, LH and RMD fare this time.
- 04/27/2022
|
Labcorp initiates dividend, with an initial implied yield above 1%
- Laboratory Corp. of America Holdings LH, +0.24% , also known as Labcorp, said Thursday that it has initiated a quarterly dividend of 72 cents a share. Shareholders of record on May 19 will be paid the dividend on June 9.
- 04/07/2022
|
IHF: A Standout Performer With Strong Future Growth Prospects
- IHF: A Standout Performer With Strong Future Growth Prospects
- 03/30/2022
|
LabCorp (LH) Gains From Covance Arm Growth, Cost Pressure Ails
- LabCorp's (LH) Covance Drug Development arm is benefiting from its collaborations with leading pharmaceutical and biotechnology companies.
- 03/30/2022
|
Labcorp to Announce First Quarter Financial Results on April 28, 2022
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the first quarter of 2022 before the market opens on Thursday, April 28, 2022. The company will host a conference call and webcast beginning at 9 a.m. EDT that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. Interested parties can access the conference call by
- 03/28/2022
|
Should Value Investors Consider LabCorp (LH) Stock Now?
- Let's see if LabCorp (LH) stock is a good choice for value-oriented investors right now from multiple angles.
- 03/21/2022
|
Laboratory Corporation Of America: An Undervalued Play In The Life Sciences Space
- Laboratory Corporation of America Holdings has exhibited some nice growth over the past few years, driven in large part by the pandemic.
- 03/20/2022
|
LabCorp (LH) Gains But Lags Market: What You Should Know
- In the latest trading session, LabCorp (LH) closed at $274.33, marking a +0.11% move from the previous day.
- 03/17/2022
|
3 Stocks With High Returns on Equity
- When a company's return on equity ratio is superior to most of its competitors, it generally indicates the company has been very efficient in generating profits. Thus, investors may want to consider the following stocks since they are performing better than most of their peer group companies in terms of a higher ROE ratio.
- 03/15/2022
|
Here's Why You Should Hold on to LabCorp (LH) Stock For Now
- Investors are optimistic about LabCorp's (LH) better-than-expected results and robust base business performance.
- 03/11/2022
|
Walgreens (WBA) Expands Access to COVID-19 Test With LabCorp
- Walgreens (WBA) will enable more communities to access reliable, convenient testing services as and when required with the addition of Pixel by LabCorp COVID-19 at-home collection kit.
- 03/08/2022
|
LabCorp (LH) Expands Clinical Laboratory Services With New Pact
- LabCorp's (LH) recent collaboration will enable it to administer Ascension's hospital-based laboratories in 10 states and purchase select assets of the health system's outreach laboratory business.
- 02/15/2022
|
Laboratory Corporation of America Holdings (LH) CEO Adam Schechter on Q4 2021 Results - Earnings Call Transcript
- Laboratory Corporation of America Holdings (LH) CEO Adam Schechter on Q4 2021 Results - Earnings Call Transcript
- 02/10/2022
|
LabCorp (LH) Q4 Earnings Surpass Estimates, Margins Down
- LabCorp (LH) reports better-than-expected results for the fourth quarter, with solid contributions from the Drug Development business driving the top line.
- 02/10/2022
|
LabCorp (LH) Q4 Earnings and Revenues Beat Estimates
- LabCorp (LH) delivered earnings and revenue surprises of 14.75% and 2.95%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/10/2022
|
3 Companies to Watch for the At-Home Diagnostics Boom
- Companies that provide at-home diagnostic testing kits weren't on many investors' radars before the Covid-19 pandemic. However, many people have wished at least once in their lives that they could order specific lab tests without having to make a trip to the doctor's office.
- 02/04/2022
|
LabCorp (LH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- LabCorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/03/2022
|
5 Top-Ranked Stocks Likely to Beat Earnings Estimates
- These top-ranked stocks are likely to beat on the bottom line in their next releases.
- 01/27/2022
|
Here's Why You Should Add LabCorp (LH) to Your Portfolio Now
- Investors are optimistic about LabCorp (LH) backed by increased COVID-19 testing demand and development in high-growth areas.
- 01/24/2022
|
LabCorp (LH) Gains As Market Dips: What You Should Know
- LabCorp (LH) closed at $271.57 in the latest trading session, marking a +0.26% move from the prior day.
- 01/21/2022
|
5 Lucrative PEG Stocks for Value Investors
- Here are five value stocks, ACI, LH, PSX, FDX and SWRAY, matching our criteria.
- 01/18/2022
|
We have no upfront costs for our Covid tests, says Labcorp CEO
- Adam Schechter, Labcorp CEO, joins 'Closing Bell' to discuss how it is managing the influx of Covid test requests.
- 01/12/2022
|
Why LabCorp (LH) is Poised to Beat Earnings Estimates Again
- LabCorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 01/11/2022
|
Labcorp to Announce Fourth Quarter and Full Year 2021 Financial Results on February 10, 2022
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the fourth quarter and full year 2021 before the market opens on Thursday, February 10, 2022. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings release and accompanying financial information will be posted on the Labcorp Investor Relations website. Interested parties can access the conference
- 01/10/2022
|
4 Momentum Picks Screened on Driehaus Strategy
- COWN, LH, BBWI, and ARCB qualified as the momentum picks for the day, using the Driehaus strategy.
- 01/10/2022
|
Best Value Stocks to Buy for January 6th
- M, LH, and SEKEY made it to the Zacks Rank #1 (Strong Buy) value stocks list on January 6, 2022
- 01/06/2022
|
LabCorp (LH) Soars to 52-Week High, Time to Cash Out?
- LabCorp (LH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- 01/03/2022
|
LabCorp (LH) to Expand Oncology Portfolio With Latest Buyout
- LabCorp's (LH) acquisition of PGDx will position the company at the forefront of driving better patient outcomes in oncology.
- 12/27/2021
|
LH vs. WST: Which Stock Should Value Investors Buy Now?
- LH vs. WST: Which Stock Is the Better Value Option?
- 12/24/2021
|
5 Momentum Stocks Bargain Hunters Would Love Chasing
- Given the prevailing sentiment in the market, Academy Sports (ASO), Avis Budget (CAR), Laboratory Corporation (LH), Penske Automotive (PAG) and West Fraser (WFG) are expected to give handsome returns to momentum investors.
- 12/24/2021
|
Labcorp Bolsters Liquid Biopsy Capabilities With $450M PGDx Acquisition
- Laboratory Corp of America Holdings (NYSE: LH) has agreed to acquire Personal Genome Diagnostics Inc (PGDx), a cancer genomics firm with a portfolio of comprehensive liquid biopsy and tissue-based products. Labcorp will pay $450 million in cash at closing and up to an additional $125 million on achieving future performance milestones.
- 12/23/2021
|
Here's Why You Should Add LabCorp (LH) to Your Portfolio Now
- Investors are optimistic about LabCorp's (LH) strong third-quarter 2021 results and raised guidance.
- 12/22/2021
|
Labcorp, Quidel: Omicron Brings Covid Testing Stocks Back In Focus
- Our indicative theme on Covid-19 Testing Stocks – which includes companies that produce or carry out tests for Covid-19 infections - is up by 24% year-to-date, roughly in line with the S&P 500. While we were somewhat cautious about the long-term prospects for Covid-19 testing stocks in 2020.
- 12/21/2021
|
LabCorp (LH) Upgraded to Strong Buy: What Does It Mean for the Stock?
- LabCorp (LH) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 12/15/2021
|
Best Growth Stocks to Buy for December 15th
- CC, LH, and HCCI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 15, 2021
- 12/15/2021
|
Is LabCorp (LH) Outperforming Other Medical Stocks This Year?
- Here is how LabCorp (LH) and Maravai LifeSciences Holdings, Inc. (MRVI) have performed compared to their sector so far this year.
- 12/10/2021
|
3 Low Price-to-Median-Price-Sales Value Stocks
- When looking for bargains, investors may want to consider the following three companies, as their stocks have low price-to-median-price-sales values when compared to the average of the S&P 500 (which stands at around 1.71 as of the writing of this article).
- 12/09/2021
|
LH vs. WST: Which Stock Should Value Investors Buy Now?
- LH vs. WST: Which Stock Is the Better Value Option?
- 12/08/2021
|
Has LabCorp (LH) Outpaced Other Medical Stocks This Year?
- Here is how LabCorp (LH) and Maravai LifeSciences Holdings, Inc. (MRVI) have performed compared to their sector so far this year.
- 11/24/2021
|
Are Investors Undervaluing These Medical Stocks Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 11/23/2021
|
Rapid Covid-19 tests in high demand ahead of Thanksgiving
- CNBC's Meg Tirrell joins 'Squawk Box' to report on the increased demand for Covid-19 tests ahead of the Thanksgiving holiday.
- 11/23/2021
|
LH vs. COO: Which Stock Should Value Investors Buy Now?
- LH vs. COO: Which Stock Is the Better Value Option?
- 11/22/2021
|
LabCorp (LH) to Expand Nonclinical Development With New Buyout
- LabCorp's (LH) acquisition of Toxikon can expand its full-service drug development and medical device solutions portfolio.
- 11/19/2021
|
Here's Why You Should Add LabCorp (LH) to Your Portfolio Now
- Investors are optimistic about LabCorp (LH) backed by consistent recovery across its businesses and raised 2021 guidance.
- 11/15/2021
|
Labcorp In Talks To Merge Some Covance Assets With Syneos: Bloomberg
- Laboratory Corp of America Holdings (NYSE: LH) is in talks to combine some of its assets with Syneos Health Inc (NASDAQ: SYNH), reports Bloomberg citing people with knowledge of the matter. The companies are discussing a deal in which part of LabCorp's Covance clinical research division would merge with Syneos.
- 11/12/2021
|
5 Stocks Likely to Give Sweet Surprises on Earnings
- These top-ranked stocks are likely to beat on the bottom line in their next releases.
- 11/08/2021
|
LH vs. COO: Which Stock Should Value Investors Buy Now?
- LH vs. COO: Which Stock Is the Better Value Option?
- 11/05/2021
|
Will LabCorp (LH) Gain on Rising Earnings Estimates?
- LabCorp (LH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 11/02/2021
|
Laboratory Corporation of America Holdings (LH) CEO Adam Schechter on Q3 2021 Results - Earnings Call Transcript
- Laboratory Corporation of America Holdings (LH) CEO Adam Schechter on Q3 2021 Results - Earnings Call Transcript
- 10/28/2021
|
LabCorp (LH) Q3 Earnings and Revenues Beat Estimates
- LabCorp (LH) delivered earnings and revenue surprises of 42.98% and 13.53%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 10/28/2021
|
Is a Surprise Coming for LabCorp (LH) This Earnings Season?
- LabCorp (LH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 10/27/2021
|
LH or ALGN: Which Is the Better Value Stock Right Now?
- LH vs. ALGN: Which Stock Is the Better Value Option?
- 10/20/2021
|
Why LabCorp (LH) Could Beat Earnings Estimates Again
- LabCorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 10/19/2021
|
Here's Why LabCorp (LH) is a Strong Value Stock
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 10/14/2021
|
Labcorp's At Home Collection Kit Gets EUA Nod For Combined COVID-19 and Flu Detection
- The FDA has granted Emergency Use Authorization (EUA) to Laboratory Corp of America Holdings's (NYSE: LH) combined home collection kit to detect COVID-19 and influenza A/B simultaneously in individuals as young as 2 years of age. The kit will be available at no upfront cost to those who meet clinical guidelines.
- 10/01/2021
|
Labcorp Receives Emergency Use Authorization for At Home Collection Kit for Combined COVID-19 and Flu Detection
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a combined home collection kit that detects COVID-19 and influenza A/B simultaneously in individuals as young as 2 years of age. The kit will be available at no upfront cost to those who meet clinical guidelines, which may include experiencing symptoms, being exposed to someone with
- 10/01/2021
|
Labcorp to Announce Third Quarter Financial Results on October 28, 2021
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the third quarter of 2021 before the market opens on Thursday, October 28, 2021. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings release and accompanying financial information will be posted on the Labcorp Investor Relations website. Interested parties can access the conference call by diali
- 09/28/2021
|
Labcorp (LH): Strong Industry, Solid Earnings Estimate Revisions
- Labcorp (LH) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 09/27/2021
|
3 Diagnostics Stocks in Focus on Biden's Delta Variant Mandate
- Stocks like Quest Diagnostics (DGX), Quidel Corporation (QDEL) and LabCorp (LH) are the right picks now, thanks to rising COVID-19 testing demand.
- 09/14/2021
|
Labcorp Completes Acquisition of Myriad Autoimmune's Vectra Testing Business
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has closed its acquisition of select operating assets and intellectual property (IP) from Myriad Genetics' autoimmune business unit, including the Vectra® rheumatoid arthritis (RA) assay. Earlier this year, Labcorp entered into a definitive agreement to acquire Myriad's Vectra test, related IP and other RA assets, bolstering its scientific leadership in rheumatology. Specific t
- 09/13/2021
|
Labcorp to Speak at Morgan Stanley 19th Annual Global Healthcare Conference
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of its executive management team will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Monday, Sept. 13 at 3:30 p.m. ET. A live webcast of the presentation will be available via the Investor Relations section of the company's website at www.Labcorp.com and archived for replay. About Labcorp Labcorp is a leading global
- 09/08/2021
|
Labcorp Increases Minimum Hourly Wage To $15
- Laboratory Corp of America Holdings (NYSE: LH) has increased the minimum hourly wage for U.S.-based employees to $15 from $10.95. The Company joins several other firms in implementing measures to retain staff amid a nationwide labor shortage.
- 09/03/2021
|
Labcorp Raises Minimum Hourly Wage to $15 Per Hour
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced it has increased the minimum hourly wage for United States (U.S.)-based, non-union employees to $15, effective September 2021. “At the core of our ability to innovate and meet customer and patient needs is the diverse talent that we have across all of Labcorp,” said Adam Schechter, chairman and CEO of Labcorp. “To that end, we will continue to invest in our employees. I am grateful for
- 09/02/2021
|
Labcorp (LH) Base Business Grows Amid a Tough Volume Scenario
- LabCorp (LH) plans to acquire the autoimmune business unit from Myriad Genetics, including Vectra, a rheumatoid arthritis assay.
- 08/30/2021
|
Labcorp and 4 Other Stocks Can Boast Value and Momentum
- Twice a year in this column, I hunt for stocks that seem to possess both value and momentum. Even though the market has hit records lately, it's still possible to find stocks that have both qualities.
- 08/30/2021
|
Here's Why You Should Hold on to LabCorp (LH) Stock Now
- Investors are optimistic about LabCorp (LH) on recovery in its base business and a raised 2021 guidance.
- 08/30/2021
|
LabCorp (LH) Inks Deal to Assess Disparities in Drug Development
- LabCorp (LH) and CCORN partner to develop a patient registry and biobank to help design cancer clinical trials in diverse populations.
- 08/20/2021
|
Labcorp and Community Clinical Oncology Research Network Collaborate to Assess Social and Economic Impacts of Disparities in Cancer Care
- BURLINGTON, N.C. & EDISON, N.J.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, and Community Clinical Oncology Research Network, LLC (CCORN), a leading research organization, today announced their collaboration to better understand the impact of disparities in precision medicine for people with cancer. Information gathered from a patient registry and biobank will be used to help design future cancer clinical trials in diverse populations. “Labcorp and CCORN are jo
- 08/19/2021
|
Laboratory Corporation Of America Holdings: Leading Diagnostics Provider, 18%-20% Yearly Return With Safety And Value
- Laboratory Corp is a no-brainer choice for investors looking for a stable, long-term growth stock. The stock currently is rated A for value as determined by the Seeking Alpha system, further adding to the appeal.
- 08/18/2021
|
Labcorp Is Up 61% And Looks Set For More Growth
- Labcorp Is Up 61% And Looks Set For More Growth
- 08/18/2021
|
Labcorp Acquires Digital Pregnancy Platform Provider For Undisclosed Amount
- The clinical testing giant Laboratory Corp of America Holdings (NYSE: LH) picked up Ovia Health, developer of a digital platform for tracking pregnancies and coaching new parents through infancy. The acquisition marks a new step in Labcorp's commercial push into the booming femtech (female technology) space after an investment in Ovia last year.
- 08/13/2021
|
National Kidney Foundation and Labcorp Data Show Millions Aren't Tested for Kidney Disease
- NEW YORK, Aug. 5, 2021 /PRNewswire/ -- New data suggest that millions of patients most at-risk for life-threatening kidney disease are unaware they have it because they are not tested according to clinical practice guidelines despite their risk. The study, by authors from the National Kidney Foundation (NKF) and Labcorp, appears today in the journal Diabetes Care.
- 08/05/2021
|
Laboratory Corporation of America Holdings (LH) CEO Adam Schechter on Q2 2021 Results - Earnings Call Transcript
- Laboratory Corporation of America Holdings (LH) CEO Adam Schechter on Q2 2021 Results - Earnings Call Transcript
- 07/29/2021
|
LabCorp (LH) Q2 Earnings Surpass Estimates, 2021 View Raised
- LabCorp (LH) Diagnostics revenues in the second quarter increase significantly on organic Base Business volume improvements despite decelerating demand for COVID-19 testing.
- 07/29/2021
|
LabCorp (LH) Q2 Earnings and Revenues Beat Estimates
- LabCorp (LH) delivered earnings and revenue surprises of 8.69% and 7.08%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 07/29/2021
|
Recap: Laboratory Corp Q2 Earnings
- Shares of Laboratory Corp (NYSE:LH) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share increased 138.52% over the past year to $6.13, which beat the estimate of $5.57.
- 07/29/2021
|
Labcorp Announces 2021 Second Quarter Results
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading life sciences company, today announced results for the second quarter ended June 30, 2021, and raised full-year guidance. “Our strategy focusing on science, innovation and technology led to strong second quarter results as we continued to advance health care and patient experiences,” said Labcorp Chairman and CEO Adam Schechter. “Patients and pharmaceutical clients accelerated their return to normal health care and business activi
- 07/29/2021
|
LabCorp (LH) to Report Q2 Earnings: What's in the Cards? (revised)
- LabCorp's (LH) second-quarter base-business performance is expected to have registered a faster recovery rate compared to the first quarter.
- 07/28/2021
|
LabCorp (LH) Soars to 52-Week High, Time to Cash Out?
- LabCorp (LH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- 07/26/2021
|
LabCorp (LH) to Report Q2 Earnings: What's in the Cards?
- LabCorp's (LH) second-quarter base-business performance is expected to have registered a faster recovery rate compared to the first quarter.
- 07/23/2021
|
LH vs. CNMD: Which Stock Should Value Investors Buy Now?
- LH vs. CNMD: Which Stock Is the Better Value Option?
- 07/16/2021
|
The Perfect 10 Portfolio Returned 69% Last Year
- To call a beautiful woman a “Perfect 10” these days would be considered chauvinistic and outdated.
- 07/12/2021
|
Here's Why You Should Add LabCorp (LH) Stock to Your Portfolio
- Investors are optimistic about LabCorp (LH) backed by strong diagnostic arm growth and improvement in base business.
- 07/12/2021
|
5 Lucrative Picks Based on PEG Ratio for GARP Investors
- Here are five out of the 10 stocks, ASO, LB, PTR, LH, and HIBB, based on hybrid GARP investment strategy.
- 07/06/2021
|
LabCorp (LH) Expands Testing Portfolio With the Launch of CDx
- LabCorp's (LH) new test expands the company's leadership in bringing testing solutions for new precision medicines used to treat patients with lung cancer.
- 07/05/2021
|
Labcorp to Announce Second Quarter Financial Results on July 29, 2021
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the second quarter of 2021 before the market opens on Thursday, July 29, 2021. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings release and accompanying financial information will be posted on the Labcorp Investor Relations website. Interested parties can access the conference call by dialing
- 07/02/2021
|
Labcorp Launches Companion Diagnostic for Amgen's Newly-approved Lung Cancer Therapy
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp® (NYSE: LH), a leading global life sciences company, today announced the availability of therascreen® KRAS PCR Mutation Analysis, a companion diagnostic to identify patients with non-small cell lung cancer (NSCLC) who are eligible for treatment with LUMAKRAS™ (sotorasib), a new treatment option developed by Amgen. Labcorp's oncology platform brings together the company's leadership in diagnostic testing with its comprehensive drug development services,
- 07/01/2021
|
LH vs. CNMD: Which Stock Is the Better Value Option?
- LH vs. CNMD: Which Stock Is the Better Value Option?
- 06/30/2021
|
LabCorp (LH), Molecular Loop Team Up for COVID-19 Test Research
- The SARS-CoV-2 Research Sequencing Panel will help LabCorp (LH) sequence thousands of complete coronavirus genomes each week from positive patient samples.
- 06/24/2021
|
Labcorp Adopts Molecular Loop SARS-CoV-2 Research Sequencing Panel for Large-Scale Viral Surveillance
- NEWTON, Mass., June 22, 2021 /PRNewswire/ -- Molecular Loop Biosciences, Inc. , a company redefining the simplicity of targeted sequencing, announced today that its SARS-CoV-2 Research Sequencing Panel has been deployed by Labcorp (NYSE: LH), a leading global life sciences company, to help sequence thousands of complete coronavirus genomes each week from positive patient samples.
- 06/22/2021
|
2 Incredibly Cheap Healthcare Stocks
- These companies dominate a vital medical industry niche, and their valuations are near their all-time lows.
- 06/18/2021
|
LabCorp (LH) Boosts Precision Oncology With INSIGHT NGS Launch
- LabCorp (LH) enables evidence-based, personalized treatment suggestions based on the genomic profiling of a patient's solid tumor with the launch of new test.
- 06/15/2021
|
Labcorp And OmniSeq Launch INSIGHT℠, Next-Generation Sequencing Platform to Advance Precision Oncology
- BUFFALO, N.Y., June 14, 2021 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, and OmniSeq, a CAP-accredited, molecular diagnostic innovation of Roswell Park Comprehensive Cancer Center, today announced the launch of OmniSeq INSIGHT℠, a comprehensive genomic and immune profiling, tissue-based test that integrates next-generation sequencing (NGS) technology.
- 06/14/2021
|
7 Healthcare Stocks to Buy for Changing Demographics
- These seven healthcare stocks are in a good position to take off as baby boomers continue to age into retirement. The post 7 Healthcare Stocks to Buy for Changing Demographics appeared first on InvestorPlace.
- 06/11/2021
|
LabCorp's (LH) Pixel Home Collection Kit Now in WBA Stores
- According to LabCorp (LH), the on-demand delivery option is useful for individuals showing symptoms of COVID-19 infection who want to be tested without potentially infecting others.
- 06/09/2021
|
Pixel by Labcorp® COVID-19 PCR Test Home Collection Kits Now Available Nationwide at Walgreens and Through On-Demand Delivery
- BURLINGTON, N.C. & DEERFIELD, Ill.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company today announced that Pixel by Labcorp® COVID-19 PCR Test Home Collection Kits are now in 6,000 Walgreens stores nationwide and through Walgreens collaborations with on-demand delivery services DoorDash and Instacart. The newly expanded availability and delivery option advances Walgreens and Labcorp's efforts to increase COVID-19 testing access in communities across the U.S., especiall
- 06/08/2021
|
5 Predictable Stocks Gurus Are Buying
- According to the GuruFocus All-in-One Screener, a Premium feature, the following companies have high business predictability ratings and wide margins of safety as of June 8.
- 06/08/2021
|
3 Medical Diagnostics Stocks in Focus on Long-Term Potential
- MedTech testing stocks like Quest Diagnostics Incorporated (DGX), Thermo Fisher Scientific, Inc. (TMO) and Laboratory Corporation of America Holdings (LH) are likely to survive post-pandemic.
- 06/07/2021
|
This Biotech Just Made History. Will Its Stock Follow?
- Twenty years after the human genome was sequenced, a new wave of discovery has begun.
- 06/04/2021
|
Labcorp to Introduce Combined Oncology Offering at 2021 ASCO® Annual Meeting
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced the introduction of its combined Labcorp oncology platform at the virtual 2021 American Society of Clinical Oncology (ASCO®) Annual Meeting held June 4-8. Labcorp's oncology platform brings together the company's leadership in diagnostic testing with its comprehensive drug development services, delivering targeted solutions for oncology by leveraging breakthrough science and insights f
- 06/02/2021
|
Laboratory Corp: A Solid Margin of Safety
- Like many other diagnostics and drug development companies, Laboratory Corp. of America Holdings ( LH , Financial) saw its base business decline as Covid-19 took hold. Fewer patients sought routine medical care and many clinical trials were suspended, leading to a decline in its two streams of revenue.
- 05/25/2021
|
Labcorp Study Suggests COVID-19 Antibodies Remain at Least 10 Months After Infection
- BURLINGTON, N.C.--(BUSINESS WIRE)--Nearly 87% of naturally infected COVID-19 patients maintained antibodies to SARS-CoV-2 proteins for at least 10 months, according to a new Labcorp (NYSE: LH) analysis of specimens from 39,086 individuals. The study, published May 24 in The Lancet-affiliated EClinicalMedicine, offers real-world evidence of the body's response to the virus and the possibility of protection against future infection. It is the largest known COVID-19-related study by specimen volum
- 05/24/2021
|
Jana Partners' Top 5 Trades in the 1st Quarter
- Jana Partners (Trades, Portfolio), a New York-based investment firm, disclosed this week that its top five trades during the first quarter included the reduction in its holdings in Perspecta Inc. ( PRSP , Financial) and Encompass Health Corp. ( EHC , Financial), the closure of its position in Bloomin Brands Inc. ( BLMN , Financial) and boosts to its stakes in Treehouse Foods Inc. ( THS , Financial) and Laboratory Corp of America Holdings ( LH , Financial).
- 05/21/2021
|
A Trio of High Return Non-Cyclical Stocks for the Value Investor
- If seeking for high return investments amid non-cyclical stocks, investors could be interested in the three companies listed below, as their earnings yields (as calculated via Joel Greenblatt ( Joel Greenblatt , Portfolio)'s method) are outperforming the U.S. market.
- 05/20/2021
|
LabCorp's (LH) New Bioanalytical Lab to Boost APAC Operation
- The new laboratory by LabCorp (LH) is set to enable faster data turnaround for early phase trials in Asia-Pacific markets.
- 05/20/2021
|
Labcorp to Expand Bioanalytical Services With Integrated Laboratory in Singapore
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced the expansion of its drug development offering in the Asia-Pacific region with the addition of bioanalytical services in Singapore. “Singapore is a crucial region for strengthening Labcorp's extensive global presence, offering our clients—both in-region and international—a complementary site to support their bioanalytical studies,” said Stephane Sidobre, vice president and head of Labc
- 05/19/2021
|
LabCorp's (LH) Pixel Kit Gets EUA for Younger Population
- LabCorp (LH) becomes the first major commercial laboratory to offer a COVID-19 PCR Test Home Collection Kit for children and adolescents.
- 05/18/2021
|
Labcorp Prices $500,000,000 in 1.550% Senior Notes Due 2026 and $500,000,000 in 2.700% Senior Notes Due 2031
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH) (“Labcorp”) announced today that it has priced its offering of $1,000,000,000 in senior notes. The offering consists of two tranches: $500,000,000 aggregate principal amount of 1.550% Senior Notes due 2026 (the “2026 Notes”) and $500,000,000 aggregate principal amount of 2.700% Senior Notes due 2031 (the “2031 Notes” and, together with the 2026 Notes, the “Notes”). The Notes will bear interest from May 26, 2021, payable semi-annually on June
- 05/12/2021
|
Labcorp and the U.S. Department of Health and Human Services Join Forces to Raise Awareness of COVID-19 Treatments
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, is working with the U.S. Department of Health and Human Services (HHS) to raise awareness of potentially lifesaving monoclonal antibody COVID-19 therapies. Patients who test positive using Labcorp's COVID-19 PCR test will receive information about monoclonal antibody therapeutics with their result. Additionally, Labcorp's COVID-19 site provides information about treatments and vaccines, including mono
- 05/11/2021
|
LabCorp (LH) Base Line Growth Solid, COVID-Related Sales Drop
- LabCorp's (LH) Walgreens-partnership expands to include new integrated digital experiences.
- 05/05/2021
|
4 Medical Products Stocks Set to Beat This Earnings Season
- Rebound in base sales make us optimistic about OMI, INGN, XRAY and CNTG's results this time around.
- 05/04/2021
|
GENFIT announces the launch by Labcorp of NASHnext® A Novel Noninvasive Diagnostic Test Powered by GENFIT's NIS4™ Technology to Identify Patients with At-Risk NASH
- Test Available Exclusively through Labcorp in the U.S. and Canada
- 05/03/2021
|
Laboratory Corporation of America Holdings (LH) CEO Adam Schechter on Q1 2021 Results - Earnings Call Transcript
- Laboratory Corporation of America Holdings (LH) CEO Adam Schechter on Q1 2021 Results - Earnings Call Transcript
- 04/29/2021
|
LabCorp (LH) Q1 Earnings Surpass Estimates, View Raised
- LabCorp's (LH) raises 2021 guidance but projects significant sinking of COVID-related testing revenues.
- 04/29/2021
|
LabCorp (LH) Tops Q1 Earnings and Revenue Estimates
- LabCorp (LH) delivered earnings and revenue surprises of 20.08% and 7.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 04/29/2021
|
Why Earnings Season Could Be Great for LabCorp (LH)
- LabCorp (LH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 04/28/2021
|
LabCorp (LH) to Report Q1 Earnings: What's in the Offing?
- With respect to LabCorp's (LH) COVID-19 testing services wing, although extensive vaccine rollouts are ongoing, the resurgence of the virus might have once again boosted testing demand in Q1.
- 04/23/2021
|
Laboratory Corporation Of America Holdings: Valuations, Fundamentals Make Shares Attractive
- Laboratory Corporation of America Holdings shares currently look attractive on fundamental momentum and valuations. Shares come in at 19x FWD FCF and trade at average -21% discount to peer median across multiples.
- 04/21/2021
|
Labcorp Launches COVID-19 Test Kits for Small Businesses to Support Return to Work and Life Safely
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced the availability of the Pixel by Labcorp® COVID-19 PCR Test Home Collection Kit for small businesses, an initiative aimed at providing fast, convenient, and reliable testing for companies with as many as 120 employees. Labcorp Employer Services currently provides COVID-19 testing and vaccination services for larger organizations and communities. The small business offering enables bulk
- 04/20/2021
|
Here's Why You Should Hold on to LabCorp (LH) Stock Now
- Investors are optimistic about LabCorp (LH) backed by its strong diagnostic arm growth and progress in Covance business.
- 04/20/2021
|
A Trio of Health Care Stock Picks
- When screening the market for value opportunities, one method is to pick stocks whose trailing 12-month price-to-free cash flow ratios are low compared to that of the S&P 500 Index, which stands at around 13.18 currently.
- 04/18/2021
|
Labcorp to Webcast Its Annual Meeting of Shareholders
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that its Annual Meeting of Shareholders will be webcast live beginning May 12, at 9:00 a.m. ET via the company website at www.Labcorp.com. An archived replay of the webcast will be available for one year. About Labcorp Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make cl
- 04/16/2021
|
Labcorp to Announce First Quarter Financial Results on April 29, 2021
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, will release its first quarter of 2021 financial results before the market opens on Thursday, April 29, 2021, and then will host a conference call and webcast beginning at 9:00 a.m. ET to discuss the results. The earnings release and accompanying financial information will be posted on the Labcorp Investor Relations website. Interested parties can access the conference call by dialing 1-877-898-8036 w
- 03/30/2021
|
3 Stocks for GARP Investors
- There are investors who believe growth is very important as long as you do not pay too much for it. Such investors are looking for the union of growth and value in stocks when screening the market.
- 03/30/2021
|
Labcorp Appoints Johnson & Johnson Executive Kathryn Wengel to the Board of Directors
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced the appointment of Kathryn Wengel, current Executive Vice President and Chief Global Supply Chain Officer at Johnson & Johnson, as an independent member of Labcorp's Board of Directors, effective immediately. In connection with this appointment, the Labcorp Board will expand from 9 to 10 directors. “I am pleased to welcome a renowned healthcare industry veteran like Kathy to the La
- 03/26/2021
|
LabCorp (LH) Banks on Structural Review Plan for Solid Returns
- LabCorp (LH) plays a critical role in terms of COVID-19-related developments as well as makes progress in other key therapeutic areas.
- 03/25/2021
|
5 MedTech Growth Stocks Gaining Ground in 2021 Amid Pandemic
- Here are a few MedTech stocks, ABT, HOLX, HRC, IDXX, LMAT, which have held their ground amid the pandemic and can turn out to be wise investment choices for 2021.
- 03/25/2021
|
LabCorp (LH) Moves 4.9% Higher: Will This Strength Last?
- LabCorp (LH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- 03/25/2021
|
Labcorp Business Update
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading life sciences company, today issued the following statement: Labcorp continues to make progress executing our strategy and capitalizing on the power of our diagnostic and drug development businesses. We are successfully accelerating growth across our platform, while playing a critical role in the fight against COVID-19 and helping our clients develop next-generation solutions for other key therapeutic areas such as oncology, liver
- 03/23/2021
|
Dr. Marcia Eisenberg, Chief Scientific Officer of Labcorp Diagnostics, Named a Healthcare Businesswoman's Association Luminary
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that Marcia Eisenberg, Ph.D., chief scientific officer of Labcorp Diagnostics, was recognized by the Healthcare Businesswomen's Association (HBA) as a 2021 Luminary. This title honors the 30-plus years of Dr. Eisenberg's career, which she has dedicated to innovations in healthcare and science, as well as her efforts in the advancement of women in the industry. “I am honored to have bee
- 03/23/2021
|
Fed Eyes Faster Recovery in 2021: 3 MedTech Stocks to Buy
- MedTech stocks like INMD, BASI and SMLR are expected to maintain market-beating momentum in 2021.
- 03/19/2021
|
Labcorp Scheduled to Speak at KeyBanc Capital Markets' Life Sciences and MedTech Investor Forum
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a virtual fireside chat at KeyBanc Capital Markets' Life Sciences and MedTech Investor Forum on Wednesday, March 24 at 2:00 p.m. ET. A live webcast of the presentation will be available via the company website at www.Labcorp.com and archived for replay. About Labcorp Labcorp is a leading global life sciences company that
- 03/19/2021
|
3 Stocks to Capitalize on Promising Dental Supplies Industry
- 3 Stocks to Capitalize on Promising Dental Supplies Industry
- 03/10/2021
|
Circle Medical to Offer Labcorp's At Home COVID-19 Self-Collection Test and Announces Clinical Expansion to Austin and San Diego Markets
- SAN FRANCISCO--(BUSINESS WIRE)--Circle Medical, a digital-first primary care practice, will be offering a convenient at home COVID-19 self-collection test kit in partnership with Labcorp (NYSE: LH). Together with Circle Medical's primary care telemedicine service, Circle Medical's patients will now have access to an end-to-end COVID-19 testing solution that is covered by most insurance plans. This home based COVID-19 self-collection kit is now available to patients in California, New York, Texa
- 03/10/2021
|
Labcorp Named to Fast Company's List of the World's Most Innovative Companies for 2021
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has been named to Fast Company magazine's list of 2021 Most Innovative Companies. Since 2008, the annual list has been the definitive source for recognizing the organizations that are transforming industries and shaping society. Labcorp was cited for its leadership in science, innovation, and healthcare in the fight against COVID-19 by advancing testing, partnering with biophar
- 03/09/2021
|
TrakCel Fuels Growth and Increased Market Access Through Strategic Investment Round
- CARDIFF, Wales--(BUSINESS WIRE)--TrakCel, a leading supplier of cellular orchestration solutions supporting the cell and gene therapy industry, today announces that it has closed its latest funding round led by AmerisourceBergen and Labcorp (NYSE: LH). These strategic investments enable further transformation of TrakCel's cellular therapy orchestration solution, growth of its existing partner ecosystem, and continued global expansion. The company will use both the investment and the combined ex
- 03/03/2021
|
Jana Partners' Top 4 Trades of the 4th Quarter
- Jana Partners (Trades, Portfolio), a New York-based investment firm, disclosed last week that its top four trades during the fourth quarter of 2020 featured new holdings in Laboratory Corp of America Holdings (NYSE:LH) and Treehouse Foods Inc. (NYSE:THS), a position boost in Encompass Health Corp. (NYSE:EHC) and the closure of its position in Calloway Golf Co. (NYSE:ELY).
- 02/25/2021
|
Walgreens to Make Pixel by Labcorp™ COVID-19 PCR Test Home Collection Kit Available Over-The-Counter at Stores Nationwide
- DEERFIELD, Ill. & BURLINGTON, N.C.--(BUSINESS WIRE)--As part of Walgreens ongoing efforts to increase access to COVID-19 testing in communities across the U.S., the company announced today it has entered into an agreement with Labcorp™ to sell Pixel by Labcorp COVID-19 PCR Test Home Collection Kits over-the-counter in up to 6,000 Walgreens stores nationwide beginning in spring of this year. Walgreens is making significant strides to increase on-site testing capacity at more than 5,000 Walgreens
- 02/24/2021
|
Pacific Biosciences' (PACB) Sequel II Gets Deployed by LabCorp
- Pacific Biosciences' (PACB) Sequel II HiFi sequencing gets utilized by LabCorp to detect SARS-COV-2 variants in the United States.
- 02/23/2021
|
Labcorp is Scheduled to Speak at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a virtual fireside chat at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference on Thursday, Feb. 25 at 1:30 p.m. ET. A live webcast of the presentation will be available via the company website at www.Labcorp.com and archived for replay. About Labcorp Labcorp is a leading global life sciences c
- 02/23/2021
|
LabCorp's (LH) New Antigen Test to Spot Active COVID-19 Virus
- LabCorp's (LH) new antigen test is the newest development to detect COVID-19 infection at every single stage, from diagnostic testing to vaccination trails.
- 02/22/2021
|
Laboratory Corporation of America Holdings (LH) CEO Adam Schechter on Q4 2020 Results - Earnings Call Transcript
- Laboratory Corporation of America Holdings (LH) CEO Adam Schechter on Q4 2020 Results - Earnings Call Transcript
- 02/11/2021
|
Here's How Labcorp Trounced Wall Street Estimates in Q4
- The laboratory services giant continued to profit mightily from its COVID-19 testing business.
- 02/11/2021
|
LabCorp (LH) Q4 Earnings Beat Estimates, Margins Expand
- LabCorp's (LH) 2021 guidance projects significant downfall in COVID-related testing revenues.
- 02/11/2021
|
LabCorp (LH) Q4 Earnings and Revenues Beat Estimates
- LabCorp (LH) delivered earnings and revenue surprises of 31.18% and 12.94%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 02/11/2021
|
Labcorp Announces 2020 Fourth Quarter and Full Year Results and Provides 2021 Guidance
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading life sciences company, today announced results for the fourth quarter and year ended December 31, 2020, and full year 2021 guidance. “Labcorp's science and innovation throughout the pandemic led to strong performance in the quarter and for the full year. In addition to our leadership in testing, our capabilities are being leveraged to identify variants to the virus through genetic sequencing and to support biotechnology and pharma
- 02/11/2021
|
Why LabCorp (LH) Might Surprise This Earnings Season
- LabCorp (LH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 02/10/2021
|
Labcorp Announces Key Appointments to Oncology Leadership Team
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced the appointments of Prasanth Reddy, MD, MPH, and Robert Phillips, PhD, to its oncology team, advancing Labcorp's leadership position and capabilities in cancer diagnosis, treatment, and drug development. Dr. Reddy will serve as senior vice president and enterprise oncology head of the company's enterprise oncology unit, and Dr. Phillips will be vice president and head of enterprise onc
- 02/09/2021
|
Higher Testing Volume to Aid LabCorp's (LH) Q4 Earnings
- LabCorp's (LH) fourth-quarter base-business performance is expected to have registered slower recovery rate compared to the third quarter.
- 02/08/2021
|
Why LabCorp Is Set For Long-Term Success
- Why LabCorp Is Set For Long-Term Success
- 02/02/2021
|
Testing Space in Focus Again Thanks to New Wave of Coronavirus
- The resurgence in coronavirus infections is drawing attention back to the diagnostic testing space.
- 01/13/2021
|
LabCorp CEO says Covid vaccine recipients don't need to be tested for antibodies afterward
- "We still have to understand a lot more about the vaccines, know what to measure, how to measure," LabCorp CEO Adam Schechter told CNBC.
- 01/12/2021
|
LabCorp CEO discusses Covid mutations
- Adam Schechter, LabCorp CEO, joins 'Closing Bell' to discuss the state of testing in the U.S., Covid mutations and his thoughts on what it will take to reach herd immunity.
- 01/12/2021
|
Labcorp to Announce Fourth Quarter and Full Year 2020 Financial Results on February 11, 2021
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, will release its fourth quarter and full year 2020 financial results before the market opens on Thursday, Feb. 11, 2021, and then will host a conference call and webcast beginning at 9:00 a.m. ET to discuss the results. The earnings release and accompanying financial information will be posted on the Labcorp Investor Relations website. Interested parties can access the conference call by dialing 1-877
- 01/08/2021
|
Labcorp Awarded CDC Contract to Study Variants of COVID-19 Virus and Improve Public Health Response
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has been awarded a contract from the Centers for Disease Control and Prevention (CDC) to provide genomic sequencing of samples of SARS-CoV-2, the virus that causes COVID-19. This sequencing will aid the CDC in its goal of conducting a large-scale longitudinal genomic survey of the virus using a random set of samples collected from across the United States. The survey aims to pr
- 01/07/2021
|
Brian Caveney, Chief Medical Officer and President of Labcorp Diagnostics, Named to Modern Healthcare's 100 Most Influential People in Healthcare
- BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that Dr. Brian Caveney, chief medical officer and president of Labcorp Diagnostics, was recognized by Modern Healthcare as one of the 100 most influential people in healthcare in 2020. According to Modern Healthcare, editors of the publication and its readers selected the most innovative and resilient candidates who influenced the course that healthcare took during a global crisis and
- 01/06/2021
|
LabCorp's (LH) Covance Arm Stays Robust Amid Procedure Delay
- Apart from COVID-19 supports, LabCorp (LH) is making significant strides in other businesses.
- 01/05/2021
|
Top Ranked Growth Stocks to Buy for January 4th
- Top Ranked Growth Stocks to Buy for January 4th
- 01/04/2021
|
Is LabCorp (LH) a Great Value Stock Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 12/31/2020
|
Top Ranked Growth Stocks to Buy for December 30th
- Top Ranked Growth Stocks to Buy for December 30th
- 12/30/2020
|
5 Low Price-to-Book Value Stocks to Buy in the New Year
- P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high growth prospects.
- 12/29/2020
|
Create a Value-Based Portfolio With These 4 Low P/CF Stocks
- Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. ODP Corporation (ODP), Sanmina Corporation (SANM), Laboratory Corporation (LH) and Boise Cascade (BCC) boast low P/CF ratio.
- 12/29/2020
|
LabCorp (LH) Stock Sinks As Market Gains: What You Should Know
- LabCorp (LH) closed at $203.87 in the latest trading session, marking a -0.09% move from the prior day.
- 12/24/2020
|
Top Ranked Growth Stocks to Buy for December 23rd
- Top Ranked Growth Stocks to Buy for December 23rd
- 12/23/2020
|
3 Reasons Growth Investors Will Love LabCorp (LH)
- LabCorp (LH) possesses solid growth attributes, which could help it handily outperform the market.
- 12/22/2020
|
Walgreens and Labcorp Make Pixel by Labcorp™ At-Home COVID-19 Collection Kit Available Through Walgreens Find Care®
- DEERFIELD, Ill. & BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, and Walgreens today announced that the Pixel by Labcorp™ At-Home COVID-19 Collection Kit is now available from Labcorp through Walgreens Find Care®, a digital health platform available on the Walgreens app and Walgreens.com. Walgreens currently offers COVID-19 testing in more than 1,100 drive-thru locations across
- 12/21/2020
|
LabCorp (LH) Gains As Market Dips: What You Should Know
- LabCorp (LH) closed at $205.11 in the latest trading session, marking a +1.19% move from the prior day.
- 12/18/2020
|
LH vs. XRAY: Which Stock Is the Better Value Option?
- LH vs. XRAY: Which Stock Is the Better Value Option?
- 12/18/2020
|
Should Value Investors Buy LabCorp (LH) Stock?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 12/15/2020
|
Top Ranked Growth Stocks to Buy for December 15th
- Top Ranked Growth Stocks to Buy for December 15th
- 12/15/2020
|
Coronavirus testing: LabCorp receives FDA authorization for at-home COVID-19 kits
- Yahoo Finance's Alexis Christoforous and Brian Caveney, Labcorp Diagnostics President, discuss the latest at-home COVID-19 test kit. #coronavirustest #COVID19testing #athomecovidtest #athomecoronavirustests This segment originally aired on December 11, 2020.
- 12/12/2020
|
LabCorp COVID-19 test kit has just been approved for sale over-the-counter
- LabCorp has now become the first company to receive approval to sell its COVID-19 test kit over-the-counter without a prescription, according to a statement form the company. One of the largest diagnostics testing companies in the U.S., LabCorp could be a significant competitor to companies like EverlyWell, which received approvals for its at-home testing kits […]
- 12/09/2020
|
LabCorp Receives FDA Authorization to Make At-Home COVID-19 Collection Kits Available Through Retail
- BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for the Pixel by LabCorp™ COVID-19 Test Home Collection Kit to become the first to be available over the counter without requiring a prescription. The kit is currently available through the Pixel by LabCorp website, and this a
- 12/09/2020
|
New Coronavirus Tests Have These Diagnostics Companies Recalibrating
- The COVID-19 testing landscape is changing. Will that sap the growth of the incumbent leaders?
- 12/05/2020
|
Looking for a Growth Stock? 3 Reasons Why LabCorp (LH) is a Solid Choice
- LabCorp (LH) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 12/04/2020
|
4 Stocks That Stand Out on Attractive Interest Coverage Ratio
- A company that is capable of generating earnings well above its interest expense can withstand financial hardships.
- 11/27/2020
|
LabCorp (LH) Expands in New Jersey With Clinical Trial Deal
- LabCorp's (LH) Patient Direct offering will be used here to help in bringing suitable clinical trials to eligible patients directly.
- 11/26/2020
|
LabCorp Is Scheduled to Present at The 2020 Evercore ISI 3rd Annual HealthCONx Conference
- BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, today announced that members of the executive management team will participate in a virtual fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference on Thursday, Dec. 3 at 1:50 p.m. ET. A live webcast of the presentation will be available via the company website at www.LabCorp.com and archived for replay. About LabCorp La
- 11/25/2020
|
LabCorp: Making The Most Of Its Windfall Profits
- LabCorp is a mission-critical company that has been on the forefront of testing for COVID-19. I'm encouraged by the strong revenue backlog of its Covance drug development business, and by the secular growth trend of healthcare spend.
- 11/13/2020
|
Laboratory Corp. Of America Profit Nearly Triples, Flashes Improved Price Strength
- Laboratory Corporation Of America shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. The post Laboratory Corp. Of America Profit Nearly Triples, Flashes Improved Price Strength appeared first on Investor's Business Daily.
- 11/11/2020
|
The Virus Testing Stocks Pullback Opportunity (NASDAQ: CODX) (NASDAQ: FLGT) (OTC: ALST) (NYSE: LH)
- The Virus Testing Stocks Pullback Opportunity (NASDAQ: CODX) (NASDAQ: FLGT) (OTC: ALST) (NYSE: LH)
- 11/11/2020
|
Cramer on four coronavirus testing stocks worth owning
- "I bet the testing stocks have a lot more room to run," the "Mad Money" host said.
- 11/05/2020
|
Jim Cramer names 9 stocks to watch amid election results, rising cases
- "All of these names would work under both candidates," the "Mad Money" host said ahead of the presidential election.
- 11/02/2020
|
Were Hedge Funds Right About Piling Into Laboratory Corp. of America Holdings (LH)?
- In this article we will take a look at whether hedge funds think Laboratory Corp. of America Holdings (NYSE:LH) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their consensus stock picks historically outperformed the market after adjusting for known risk factors.
- 11/02/2020
|
Is Laboratory Corporation of America Holdings (LH) Outperforming Other Medical Stocks This Year?
- Is (LH) Outperforming Other Medical Stocks This Year?
- 10/30/2020
|
LabCorp Earns Membership In 95-Plus Composite Rating Club
- On Wednesday, Laboratory Corporation Of America got an upgrade for its IBD SmartSelect Composite Rating from 92 to 98. The post LabCorp Earns Membership In 95-Plus Composite Rating Club appeared first on Investor's Business Daily.
- 10/28/2020
|
Laboratory Corporation of America Holdings (LH) CEO Adam Schechter on Q3 2020 Results - Earnings Call Transcript
- Laboratory Corporation of America Holdings (LH) CEO Adam Schechter on Q3 2020 Results - Earnings Call Transcript
- 10/27/2020
|
AbbVie: I Don't Wanna Miss This Thing (NYSE:ABBV)
- 2020 is shaping up to be another record year for AbbVie. Six months into the pandemic, AbbVie has mastered the crisis better than expected and once again demonstrated the power of its strong and resilient portfolio.
- 09/22/2020
|
Tracking Wallace Weitz's Weitz Investment Management Portfolio - Q2 2020 Update
- Wallace Weitz's 13F portfolio value increased from $1.88B to $2.01B this quarter. The number of positions decreased from 69 to 65.
- 09/15/2020
|
Hailiang Education Group Inc. : Celebrates 25th Anniversary and Announces Two Strategic Projects and Three Major Actions in the New Era | MarketScreener
|
Thermo Fisher Should Buy Quest To Fully Integrate Lab Testing
- A Thermo Fisher - Quest Diagnostics merger would have numerous cost synergy and sales growth possibilities.
- 09/09/2020
|
Wall Street Breakfast: The Week Ahead
- Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
- 09/06/2020
|
Stocks To Watch: Tech Reboots And Eyes On Lululemon, Peloton & GameStop
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
- 09/05/2020
|
Tracking Larry Robbins' Glenview Capital Management Portfolio - Q2 2020 Update
- Glenview Capital Management's 13F portfolio value decreased from $3.68B to $3.63B this quarter. The number of positions decreased from 44 to 43.
- 09/04/2020
|
Broyhill Asset Management - H1 2020 Letter
- Broyhill Asset Management is a boutique investment firm, established as a family office and guided by a value orientation.
- 08/21/2020
|
Weitz Investments Cuts Liberty Global, Visa
- Firm's largest sales of the 2nd quarter Continue reading...
- 08/14/2020
|
LabCorp Will Perform Antibody Test at No Charge to Accelerate COVID-19 Blood Plasma Donation
- LabCorp (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced details of a no charge antibody testing program in response to federal health authorities’ request to increase donations of COVID-19 blood plasma. Plasma with COVID-19 antibodies may be helpful when treating patients with an active COVID-19 infection and is being evaluated as a possible treatment.
- 08/11/2020
|
Ariel Investments' John Rogers Shares Insight About Stocks, Racial Relations
- John Rogers, the first Black founder of a mutual fund complex, offers advice about investments and what this summer of agitation is telling Americans.
- 08/10/2020
|
COVID-19 Impacts: Coronavirus Test Kits Market Will Decelerate at a CAGR of Over -32% Through 2020-2024 | Spread of COVID-19 Pandemic Across the Globe to Boost Growth | Technavio
- The Global Coronavirus Test Kits Market will grow by USD 320.29 mn during 2020-2024
- 08/07/2020
|
Cross-Sector: Market Data Highlights
|
COVID-19 Impacts: Pharmaceutical Contract Research and Manufacturing Market will Accelerate at a CAGR of over 9% through 2020-2024|Advent Of Big Data to Boost Growth|Technavio
- The Global Pharmaceutical Contract Research and Manufacturing (CRAM) Market will grow by USD 69.09 bn during 2020-2024
- 08/05/2020
|
Hussman Strategic Advisors Sells Facebook, Exits Gilead
- Firm's largest sales of the 2nd quarter Continue reading...
- 08/04/2020
|
LabCorp (LH) Banks on Covance Amid Testing Volume Pressure
- LabCorp's (LH) COVID-19 related research too has been progressing well.
- 08/03/2020
|
Winning the cold war with China will require a stronger military and a more inventive economy
- The United States must counter the rise of China with a stronger military and a renewal of the U.S. economy.
- 08/03/2020
|
Exact Sciences' (EXAS) Q2 Earnings Beat, Margin Declines
- Exact Sciences' (EXAS) legacy screening business sees a decline in revenues in Q2 earnings.
- 07/31/2020
|
Thermo Fisher Long Case: Trajectory Is Clear, Buy On Value
- Strong quarter exit and clear guidance for Q4 2020 on the back of $1.3 billion in COVID-19 related sales YTD.
- 07/31/2020
|
LabCorp to offer antibody testing at no charge to support blood plasma donations as possible COVID-19 treatment
- Laboratory Corp. of America Holdings said Thursday it is planning to create a program offering total antibody testing at no charge as a way to support blood plasma donations as a treatment for the coronavirus illness COVID-19. Blood plasma is currently being evaluated as a possible treatment for patients with an active COVID-19 infection. LabCorp said it will run the program using individual patients' own doctor. "LabCorp is currently working with public health authorities and the provider community on the details of the three-month program and will provide additional information in the near future," the company said in a statement. Shares were flat in Thursday trade, but have gained 15% in the year to date, while the S&P 500 has gained 0.5%.
- 07/30/2020
|
LabCorp Working With Public Health Authorities on No-Charge Antibody Test Program to Accelerate COVID-19 Blood Plasma Donation
- LabCorp (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced plans to create a program to offer total antibody testing at no charge through the patient’s doctor in support of increased blood plasma donations for use as a possible COVID-19 treatment.
- 07/30/2020
|
Chemed (CHE) Q2 Earnings Beat Estimates, Margins Decline
- Chemed (CHE) witnesses solid revenue growth across key subsidiaries in Q2 earnings.
- 07/30/2020
|
Results: Laboratory Corporation of America Holdings Beat Earnings Expectations And Analysts Now Have New Forecasts
- Laboratory Corporation of America Holdings (NYSE:LH) defied analyst predictions to release its second-quarter results...
- 07/30/2020
|
CONMED (CNMD) Q2 Loss Narrower Than Expected, Revenues Top
- CONMED's (CNMD) core units - General Surgery and Orthopedic Surgery - witnessed revenue decline in Q2.
- 07/30/2020
|
Hologic (HOLX) Q3 Earnings Surpass Estimates, Margins Rise
- Hologic (HOLX) exhibited robust segmental growth in third-quarter fiscal 2020 driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.
- 07/30/2020
|
Omnicell (OMCL) Q2 Earnings Lag Estimates, Margins Down
- Omnicell's (OMCL) second-quarter revenues suffered due to slowdown in hospital purchasing decisions and product bookings owing to pandemic-led business disruptions.
- 07/29/2020
|
LabCorp (LH) Hits 52-Week High, Can the Run Continue?
- LabCorp (LH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- 07/29/2020
|
Laboratory Corp Of America Holdings (LH) Q2 2020 Earnings Call Transcript
- LH earnings call for the period ending June 30, 2020.
- 07/28/2020
|
How LabCorp Beat Wall Street's Q2 Estimates
- Laboratory Corporation of America Holdings (NYSE: LH) has sailed through the turbulent waters of 2020 pretty well so far. Here are the highlights from the company's Q2 update. LabCorp reported Q2 revenue of $2.8 billion, a 4% year-over-year decline.
- 07/28/2020
|
LabCorp (LH) Beats Q2 Earnings Estimates, Margins Decline
- LabCorp (LH) witnesses a 20.7% decline in organic volume, partially offset by acquisition volume growth of 1.2%.
- 07/28/2020
|
Is Laboratory Corporation of America Holdings (LH) Outperforming Other Medical Stocks This Year?
- Is (LH) Outperforming Other Medical Stocks This Year?
- 07/28/2020
|
LabCorp says need to run testing below full capacity to maintain shorter turnaround time
|
Laboratory Corporation of America Holdings (LH) CEO Adam Schechter on Q2 2020 Results - Earnings Call Transcript
- Laboratory Corporation of America Holdings (NYSE:LH) Q2 2020 Results Conference Call July 28, 2020 09:00 AM ET Company Participants Clarissa Willett - VP, IR Adam Schechter - Chairman and CEO Glenn Eisenberg - EVP and CFO Conference Call Participants Eric Coldwell - Baird Jack Meehan - Nephron Research Stephen Baxter - Wolf Research Lisa Gill - JP Morgan Dan Leonard - Wells Fargo Donald Hooker - KeyBanc Justin Bowers - DB Ralph Giacobbe - Citi Ricky Goldwasser - Morgan Stanley Derik de Bruin - Bank of America Dan Lawler - William Blair Presentation Operator Ladies and gentlemen, thank you for standing by, and welcome to the LabCorp of America Q2 2020 Earnings Conference Call.
- 07/28/2020
|
LabCorp (LH) Q2 Earnings and Revenues Top Estimates
- LabCorp (LH) delivered earnings and revenue surprises of 229.49% and 14.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 07/28/2020
|
Weitz Investment Management Q2 2020 Commentary
- Founded by value investor Wally Weitz in 1983, Weitz Investment Management, Inc. is a boutique, employee-owned asset management firm headquartered in Omaha, Nebraska.
- 07/23/2020
|
Laboratory Corporation Of America: Reasonably Priced And Positioned For Growth
- Laboratory Corporation of America operates as one of the top two providers of clinical lab testing services.
- 07/23/2020
|
Tributary Capital Management LLC Sells 75 Shares of Laboratory Corp. of America Holdings (NYSE:LH)
- Tributary Capital Management LLC decreased its stake in shares of Laboratory Corp. of America Holdings (NYSE:LH) by 2.5% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,900 shares of the medical research company’s stock after selling 75 shares during the quarter. Tributary Capital […]
- 07/22/2020
|
COVID-19 Impact & Recovery Analysis - Specimen Validity Testing Market (2020-2024) | Rising Consumption of Alcohol and Illicit Drugs to Boost Growth | Technavio
- The Global Specimen Validity Testing Market will grow by USD 393.04 mn during 2020-2024
- 07/22/2020
|
Healthcare Dashboard For July
- A dashboard with metrics of value, quality and momentum by industries. Value and quality scores relative to historical averages.
- 07/21/2020
|
Healthcare Dashboard For July
- A dashboard with metrics of value, quality and momentum by industries. Value and quality scores relative to historical averages.
- 07/21/2020
|
OPKO Health Is Likely To Double From Here
- Over 700,000 COVID-19 tests are being performed daily across the US. OPKO Health's wholly owned subsidiary, BioReference Labs is the nation's third-largest diagnostics laboratory.
- 07/20/2020
|
Laboratory Corp. of America Holdings (NYSE:LH) Shares Sold by CENTRAL TRUST Co
- CENTRAL TRUST Co trimmed its holdings in Laboratory Corp. of America Holdings (NYSE:LH) by 14.4% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 894 shares of the medical research company’s stock after selling 150 shares during the period. CENTRAL TRUST Co’s holdings in Laboratory […]
- 07/18/2020
|
Global Retirement Partners LLC Acquires 118 Shares of Laboratory Corp. of America Holdings (NYSE:LH)
- Global Retirement Partners LLC boosted its holdings in shares of Laboratory Corp. of America Holdings (NYSE:LH) by 19.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 711 shares of the medical research company’s stock after buying an additional 118 shares during the […]
- 07/17/2020
|
IFM Investors Pty Ltd Sells 2,537 Shares of Laboratory Corp. of America Holdings (NYSE:LH)
- IFM Investors Pty Ltd lowered its holdings in shares of Laboratory Corp. of America Holdings (NYSE:LH) by 25.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,386 shares of the medical research company’s stock after selling 2,537 shares during the […]
- 07/16/2020
|
Why LabCorp (LH) Could Beat Earnings Estimates Again
- LabCorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 07/16/2020
|
Medtronic Banks on Ventilator Sales Amid Coronavirus Crisis
- Medtronic (MDT) is currently focusing on the geographical diversification of its businesses, apart from product innovation. Also, it demonstrates a strong solvency position.
- 07/15/2020
|
Integra Reports Organic Sales Drop in Preliminary Q2 Results
- Integra (IART) projects a severe impact on revenues due to the coronavirus-led economic crisis despite sequential improvement in monthly sales performance throughout the quarter.
- 07/15/2020
|
Here's Why You Should Retain Merit Medical (MMSI) for Now
- Stocks Analysis by Zacks Investment Research covering: Medtronic PLC, Cardinal Health Inc, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated. Read Zacks Investment Research's latest article on Investing.com
- 07/15/2020
|
IPO Update: Renalytix AI Proposes IPO Terms
|
Henry Schein Banks on Dental Consumable Amid Coronavirus Woes
- Henry Schein (HSIC) seems upbeat about its dental technology business, Henry Schein One.
- 07/13/2020
|
Hologic Expands Product Portfolio With New Ultrasound System
- Hologic's (HOLX) latest cart-based ultrasound system enhances efficiency and accuracy to better meet the requirements of breast imagers and optimize patient care.
- 07/10/2020
|
Baxter Gets FDA Nod for Altapore Shape Bioactive Bone Graft
- Stocks Analysis by Zacks Investment Research covering: Baxter International Inc, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, West Pharmaceutical Services Inc. Read Zacks Investment Research's latest article on Investing.com
- 07/10/2020
|
LabCorp’s Insight Analytics Reports Help Healthcare Organizations Identify Trends for High-Risk Health Conditions and Improve Quality of Care
- LabCorp (NYSE: LH), a leading global life sciences company deeply integrated in guiding patient care, has launched Insight Analytics™ reports that support provider organizations delivering improved care, both individually and on a population level, for a range of high-risk health conditions. The reports, which reflect LabCorp’s deep analytical expertise, combine national laboratory test values with patient demographics to help identify high-risk patients, close care gaps, and support the implementation of more effective treatment practices. Healthcare organizations and public health agencies can use the reports to implement more effective treatment practices to reduce risk levels for co-morbidities including COVID-19, reducing serious complications and the need for hospitalization.
- 07/09/2020
|
Laboratory Corp. of America Holdings (LH): Are Hedge Funds Right About This Stock?
- The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
- 07/08/2020
|
LabCorp Launches At-Home Coronavirus Test Collection Kit
- LabCorp (LH) claims this to be the first digital COVID-19 service that physicians can use to remotely diagnose patients before any surgery or procedure.
- 07/08/2020
|
BD Unveils BD PurPrep Patient Preoperative Skin Preparation
- By developing fully sterile PurPrep, BD (BDX) is offering health care experts a more complete set of tools to mitigate the risk of intrinsic contamination in antiseptic solutions.
- 07/08/2020
|
Here's Why You Should Retain Avanos Medical Stock for Now
- Investor confidence is high on Avanos Medical (AVNS), thanks to solid prospects.
- 07/08/2020
|
Myriad Genetics, OptraHEALTH Partner to Offer Cancer Knowledge
- Myriad Genetics (MYGN) collaborates with OptraHEALTH to provide an AI-powered cognitive ChatBOT to serve as a genetic health knowledge platform to prospective hereditary cancer patients.
- 07/07/2020
|
LH or ALGN: Which Is the Better Value Stock Right Now?
- LH vs. ALGN: Which Stock Is the Better Value Option?
- 07/07/2020
|
Align Technology's Rollouts Aid Amid Procedural Deferrals
- Align Technology's (ALGN) new virtual solutions ensure continuity of care amid pandemic.
- 07/07/2020
|
Thermo Fisher Stock Rises on Solid Q2 Growth Expectation
- Thermo Fisher (TMO) provides encouraging Q2 guidance for organic growth.
- 07/07/2020
|
LabCorp Launches First Digital COVID-19 Service That Improves the Doctor and Patient Experience
- LabCorp (NYSE: LH) today launched the LabCorp At Home COVID-19 Test Collection Service, the first seamless digital service aimed at helping doctors protect patients by testing them for COVID-19 before surgeries and other important treatments. The service received Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) on July 1, 2020.
- 07/07/2020
|
LabCorp Launches First Digital COVID-19 Service That Improves the Doctor and Patient Experience
- LabCorp (NYSE: LH) today launched the LabCorp At Home COVID-19 Test Collection Service, the first seamless digital service aimed at helping doctors pr
- 07/07/2020
|
LabCorp to Announce Second Quarter Financial Results on July 28, 2020
- LabCorp (NYSE: LH) will release its second quarter of 2020 financial results before the market opens on Tuesday, July 28, 2020, and then will host a conference call and webcast beginning at 9:00 a.m. EDT to discuss the results. The earnings release and accompanying financial information will be posted on the LabCorp Investor Relations website.
- 07/06/2020
|
Myriad Genetics Rides on EndoPredict Amid Coronavirus Crisis
- Myriad Genetics (MYGN) expects to register an uptick in hereditary cancer volumes on account of its contract with UnitedHealthcare.
- 07/06/2020
|
Pharmaceutical Wholesale to Aid Walgreens' (WBA) Q3 Earnings?
- Walgreen Boots' (WBA) international businesses in the third quarter is likely to have suffered a huge blow with international trade coming almost to a standstill.
- 07/06/2020
|
3 Cheap MedTech Stocks Set to Gain Once Coronavirus Crisis Ebbs
- Once the pandemic-led crisis eases, these MedTech stocks will likely flourish on the back of number of positive developments.
- 07/06/2020
|
LabCorp to Announce Second Quarter Financial Results on July 28, 2020
- LabCorp (NYSE: LH) will release its second quarter of 2020 financial results before the market opens on Tuesday, July 28, 2020, and then will host a c
- 07/06/2020
|
IDEXX Gains on Diagnostics Revenues, New Coronavirus Tests
- IDEXX's (IDXX) human health business, OPTI Medical Systems' newly-developed PCR laboratory test kit named OPTI SARS-CoV-2 RNA RT-PCR gains market acceptance.
- 07/03/2020
|
Boston Scientific's (BSX) ICM System Receives FDA Approval
- Boston Scientific's (BSX) new ICM System gets the FDA's nod, thus paving way for better detection and treatment of arrhythmias.
- 07/03/2020
|
Myriad Genetics Unveils New Home DNA Sample Collection Kit
- Myriad Genetics' (MYGN) home DNA sample collection test kit for its GeneSight Psychotropic test enables physicians to remotely provide treatment options to patients with mental health issues.
- 07/02/2020
|
4 Cheap MedTech Stocks Poised to Beat Industry Post-Pandemic
- Here are some MedTech stocks which might be a solid investment option post the coronavirus blues.
- 07/01/2020
|
NextGen Virtual Visits Offers Remote Eye Care Facilities
- The offering will expand NextGen's (NXGN) ophthalmology services during the coronavirus crisis.
- 07/01/2020
|
The Manufacturers Life Insurance Company Has $13.33 Million Holdings in Laboratory Corp. of America Holdings (NYSE:LH)
- The Manufacturers Life Insurance Company boosted its holdings in Laboratory Corp. of America Holdings (NYSE:LH) by 15.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 105,458 shares of the medical research company’s stock after acquiring an additional 14,309 shares during the […]
- 07/01/2020
|
New Mexico Educational Retirement Board Reduces Holdings in Laboratory Corp. of America Holdings (NYSE:LH)
- New Mexico Educational Retirement Board reduced its holdings in shares of Laboratory Corp. of America Holdings (NYSE:LH) by 19.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,129 shares of the medical research company’s stock after selling 1,450 shares during the quarter. […]
- 07/01/2020
|
LabCorp's Xcellerate Coronavirus Solution to Aid Clinical R&D
- This solution by LabCorp (LH) takes the idea from Covance's COVID-19 Operational Recovery Team to better understand the necessities.
- 06/30/2020
|
Insurer Humana teams up with Walmart, Quest, LabCorp for COVID-19 testing
- U.S. health insurer Humana Inc will offer its members at-home COVID-19 test collection kits, as well as provide access to drive-through testings at the hundreds of neighborhood markets of Walmart Inc, it said on Tuesday. For drive-through testing, the insurer said it has tied up with the retail chain and Quest Diagnostics. Humana said new testing sites at Walmart pharmacies will be added between now and August for pharmacist-observed testing.
- 06/30/2020
|
LHC Group Inks Deal With Orlando Health to Improve HCBS
- This deal is expected to boost LHC Group's (LHCG) home and community-based business segment.
- 06/30/2020
|
Humana to Offer LabCorp At-Home COVID-19 Test Collection and Collaborate with Walmart and Quest Diagnostics to Offer Drive-Thru Testing for Humana Members
- Leading health and well-being company Humana Inc. (NYSE: HUM) announced a pilot home-testing program today that will enable at-home COVID-19 test coll
- 06/30/2020
|
Renalytix AI Looks For U.S. Public Capital In IPO Filing
- Renalytix AI has filed to raise $86 million in a U.S. IPO. The firm is developing a chronic kidney disease diagnostic system. RNLX is still in development stage
- 06/29/2020
|
Ecolab's Unit Unveils Test Kit for Cooling Water Management
- Ecolab's (ECL) bacteria test kit drastically simplifies water-chemistry testing and compliance for cooling water health.
- 06/29/2020
|
LabCorp Introduces Xcellerate® COVID-19 Clinical Study Solution
- LabCorp (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that Covance, its drug development business, has deployed the Xcellerate® COVID-19 solution as part of its award-winning Xcellerate platform. Covance has developed a comprehensive approach to reinitiate ongoing research and start up new studies, with a focus on patient safety and study delivery. Designed in conjunction with Covance’s COVID-19 Operational Recovery Team, the Xcellerate® COVID-19 solution offers integrated data collection, actionable views of critical study data, COVID-19 targeted risk management and recovery assessment.
- 06/29/2020
|
LabCorp Neutralizing Antibody Test to Aid Coronavirus Vaccine R&D
- The information related to neutralizing antibody test of LabCorp (LH) can also be used for the screening of convalescent plasma for prophylactic and therapeutic use.
- 06/26/2020
|
STAAR Surgical (STAA) Jumps: Stock Rises 8.9%
- STAAR Surgical (STAA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
- 06/26/2020
|
Presse. Contre la grève, un petit chantage à l’emploi au Parisien
- D’habitude, quand une entreprise se découvre de nouvelles ambitions, elle embauche en conséquence. Au Parisien, c’est l’inverse...
- 06/25/2020
|
Leila Richard Touma, Grey Search Africa: “le télémanagement entraîne une remise en cause du modèle managérial traditionnel”
- Entretien avec Leila Richard Touma, fondatrice du cabinet de recrutement et chasseur de têtes Grey Search Africa. Depuis Abidjan, ils sont à la recherche des talents-clés, des talents rares et des …
- 06/25/2020
|
LabCorp Launches New Neutralizing Antibody Test
- LabCorp (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced the launch of a new test that can be used to assess the capacity of antibodies in patient plasma to inhibit the SARS-CoV-2 virus. This information could be used in the development of COVID-19 vaccines and the screening of convalescent plasma for prophylactic and therapeutic use. This neutralizing antibody test will be available to biopharmaceutical companies, hospitals, blood banks and other plasma-screening facilities.
- 06/25/2020
|
Coronavirus update: US case spike puts Texas in the eye of COVID hurricane
- The surge in hospitalizations is worrying local health officials, including those in the Texas Medical Center who warned ICU-bed capacity would be breached on Thursday.
- 06/25/2020
|
LabCorp Launches Neutralizing Antibody Test For Covid-19
- LabCorp (LH) on Thursday announced the launch of a new test targeted to assess the capacity of antibodies in patient plasma to inhibit the coronavirus.Information from the neutralizing antibody test could be used for the development of COVID-19 vaccines and for the screening of convalescent plasma for prophylactic and therapeutic use, the life sciences company said. The test will be available to biopharmaceutical companies, hospitals, blood banks and other plasma-screening facilities, it added.“By leveraging our drug development and diagnostic capabilities, we are working tirelessly to find solutions to prevent and treat COVID-19,” said Paul Kirchgraber, CEO of LabCorp’s Drug Development business. “The launch of this neutralizing antibody assay is the latest effort in our company’s commitment to accelerate the evaluation of vaccine candidates so that a successful candidate may reach patients sooner.”As the research for a safe and effective vaccine continues, some clinicians are relying on the serum collected from convalescent patients who had COVID-19 to support treatment of the severely ill. As research advances, the test may be an essential element in detecting the neutralizing antibody activity correlated with the therapeutic efficacy of convalescent plasma administration, as well as the immunity of vaccine candidates.“This assay, available only through LabCorp, is based on a proven and trusted platform that has been used for decades in the evaluation of vaccine candidates designed to prevent other viral infections, including HIV, Ebola virus, influenza virus, and respiratory syncytial virus (RSV),” Kirchgraber said.LabCorp shares have surged 51% since plunging to a low in March. The stock depreciated 3.2% to $157.09 on Wednesday.Earlier this month, Robert W. Baird analyst Eric Coldwell raised the firm's price target to $219 from $199 and maintained a Buy rating on the shares, saying that its multiple materially lags broader indices so if the company can execute, the stock potential is “tantalizing”.Overall, the stock scores 10 Buy ratings from analysts versus 3 Hold ratings adding up to a Strong Buy consensus. The $213.27 average price target indicates 36% upside potential in the shares in the coming 12 months. (See LabCorp stock analysis on TipRanks).Related News: Gilead To Acquire Stake in Cancer Drug Developer Pionyr For $275 Million Merck, BioInvent Enroll First Patient In Solid Tumor Combo Trial J&J; Fails To Overturn Baby Powder Verdict, Damages Cut To $2.12B More recent articles from Smarter Analyst: * Google Snaps Up Canadian Smart Glasses Startup North * AMC Delays Theatre Openings; Top Analyst Cuts Price Target * Inovio Presents ‘Positive’ Early Data For Covid-19 Vaccine Candidate; Shares Plunge 12% * Wells Fargo Plans To Cut Its Dividend In Q3; Top Analyst Lowers Price Target
- 06/25/2020
|
LabCorp launches new neutralizing antibody test for COVID-19
- Information from the test about the virus-fighting ability of antibodies could be used in the development of COVID-19 vaccines, the company said. The test, called the neutralizing antibody test, would be available to biopharmaceutical companies, hospitals, blood banks and other blood plasma-screening facilities. Neutralizing antibodies are associated with protective immunity against re-infection for many infectious pathogens, according to the Mayo Clinic.
- 06/25/2020
|
Here's Why You Should Add Surmodics to Your Portfolio Now
- Investor confidence is high on Surmodics (SRDX), thanks to solid prospects.
- 06/25/2020
|
LabCorp launches new antibody test for COVID-19
|
The New Normal Of The Coronavirus Pandemic: Investment Implications
- I have previously discussed my views of the coronavirus pandemic, which included the fact that many states opened too early and that greater testing was needed.
- 06/25/2020
|
NextGen Virtual Visits Supports Women Health During COVID-19
- Capital Women's Care is set to expand NextGen's (NXGN) women's healthcare services during the coronavirus emergency.
- 06/24/2020
|
CVS to offer employers COVID-19 testing program as U.S. cases rise
- As U.S. employers grapple with trying to keep workers healthy and on the job amid fresh spikes in COVID-19 cases, CVS Health Corp has begun selling companies a diagnostic testing program. The unexpected surge in COVID-19 cases in states in the South and West has increased demand in recent weeks for testing workers on a regular basis, such as every two weeks or every month, said Troy Brennan, chief medical officer of the company, which operates pharmacies, a pharmacy benefit management (PBM) service and the Aetna insurance plan. States including Florida, Arizona, and Texas, as well as Georgia, Oklahoma, South Carolina and Utah have all reported an increase in COVID-19 cases and hospitalizations in recent weeks.
- 06/24/2020
|
Masimo (MASI) Boosts Product Portfolio with New Solution
- Stocks Analysis by Zacks Investment Research covering: S&P 500, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Masimo Corporation. Read Zacks Investment Research's latest article on Investing.com
- 06/24/2020
|
What's in Store for Patterson Companies' (PDCO) Q4 Earnings?
- Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect solid performance at Dental segment.
- 06/23/2020
|
Allscripts' (MDRX) Veradigm Partners with PAN Foundation
- This partnership between Allscripts (MDRX) and PAN Foundation is expected to boost patient outcomes.
- 06/23/2020
|
Coronavirus Diagnostic Tests in High Demand: 4 Stocks in Focus
- Amid the pandemic, these four companies with strong diagnostics testing developments might show better resilience.
- 06/23/2020
|
Why using Covid-19 antigen test sensibly is important
- With a multiplicity of tests, a problem will arise with the reporting and interpretation of total testing numbers.
- 06/23/2020
|
Coronavirus en France: les professionnels du tourisme, grands oubliés de la crise
- En France, les professionnels du tourisme et de l’événementiel et de la culture, dont les activités se sont arrêtées brutalement à cause du coronavirus, se sont mobilisés ce lundi 22 juin dans plusie…
- 06/22/2020
|
Masimo Launches Masimo SafetyNet-Open to Fight Coronavirus
- Masimo's (MASI) newly-launched SafetyNet-Open has been developed to ensure health and safety during the coronavirus outbreak.
- 06/22/2020
|
Specimen Validity Testing Market 2020-2024 | Rising Consumption of Alcohol and Illicit Drugs to Boost Growth | Technavio
- The Global Specimen Validity Testing Market will grow by USD 393.04 mn during 2020-2024
- 06/22/2020
|
A catalogue of bestiality: Rapists on rampage despite public uproar - Businessday NG
- Despite the public outrage over the bugbear of rape and other sex crimes in Nigeria in recent months, the rapists have continued to defile and violate both mature girls and minors as the government institutions at both federal and state levels appear helpless as to how to tackle the rape rampage. Hardly had the anger […]
- 06/21/2020
|
PerkinElmer's Tie-Up to Boost Health Outcomes in Africa
- PerkinElmer's (PKI) partnership with ASH likely to boost newborn screening in underserved populations for better health outcomes in Africa.
- 06/19/2020
|
LH vs. ALGN: Which Stock Is the Better Value Option?
- LH vs. ALGN: Which Stock Is the Better Value Option?
- 06/18/2020
|
Accuray's New CyberKnife S7 System to Boost Patient Care
- Accuray's (ARAY) newly launched CyberKnife S7 System will enable clinicians to provide best possible care to their patients through new capabilities.
- 06/18/2020
|
3 “Strong Buy” Healthcare Stocks That Should Remain Healthy
- For those that thought the extreme market volatility was behind us, think again. Last week, another burst of volatility was brought on by concerns about the U.S. economic recovery and a second wave of COVID-19. This week, however, U.S. stocks recovered some lost ground thanks to strong retail sales data. There's a lot going on in the markets, and the only certainty is uncertainty.Against this backdrop, we turned our attention to defensive stocks in the healthcare sector. In general, these stocks provide stable earnings regardless of the stock market’s state due to the constant demand for their products or services.With this in mind, we used TipRanks’ database to identify three defensive healthcare stocks with upside potential north of 20%. Not to mention each of these companies has earned a “Strong Buy” consensus rating from the analyst community.Deciphera Pharmaceuticals (DCPH)We will start with Deciphera, a biopharmaceutical company which develops cancer medications. On May 15, the company received FDA approval for its QINLOCK™ therapy. The drug is used for the treatment of fourth-line gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract.The good news didn’t end there. On June 8, Deciphera announced that The Lancet Oncology (a medical journal) published positive results from the INVICTUS Phase 3 study of QINLOCK, which featured patients who have been previously treated with anticancer therapies. Data from the study showed a statistically significant improvement in the progression free survival in patients randomized to QINLOCK, compared with patients receiving a placebo.5-star analyst Christopher Raymond, of Piper Sandler, expressed enthusiasm for QINLOCK. Soon after the company received the FDA’s stamp of approval, the analyst said he expects “meaningful upside in coming months as the setup for the launch of QINLOCK remains quite positive.”As a result, Raymond rates DCPH an Outperform (i.e. Buy). The analyst believes the stock has more room to run, as he maintains a $75 price target. This implies upside potential of 21% from current levels. (To watch Raymond’s track record, click here)Like Raymond, other analysts are also bullish on the stock. The 11 ratings on the stock include 9 Buys, only 2 Holds and no Sells, adding up to a Strong Buy consensus rating. The average price target of $71.20 represents a possible 15% increase from the share price of $59.50. (See Deciphera stock analysis on TipRanks)Laboratory Corporation of America (LH)Up next is Laboratory Corporation of America, which operates two divisions, LabCorp Diagnostics (LCD) and Covance Drug Development. LCD provides clinical laboratory services such as blood, urine, and COVID-19 tests, while Covance offers services that help clients manage the drug development process.The company’s sales were only slightly affected by the COVID-19 pandemic. Revenue for the first quarter of 2020 was $2.8 billion, an increase of 1.2% from the prior-year quarter. The increase in revenue was due to acquisitions, partially offset by the negative impact from COVID-19. However, earnings took a bigger hit thanks to the public health crisis, as the operating loss for the quarter was $193 million, compared to operating income of $318 million in the first quarter of 2019.J.P. Morgan analyst Lisa Gill believes Laboratory is better positioned than the competition because of its income diversity, with it also less exposed to upcoming Medicare cuts. To provide additional support for her bullish thesis, the 5-star analyst cites improving trends in the company’s core business.To this end, Gill rates LH an Overweight (i.e. Buy), while raising her price target from $118 to $223. The new figure implies upside potential of 31% from current levels. (To watch Gill’s track record, click here)Turning now to the rest of the Street, most other analysts are on the same page. Laboratory has a Strong Buy analyst consensus rating comprised of 10 Buys, 3 Holds and no Sell ratings. The average price target on the stock is $213.27, which suggests 25% upside potential. (See LH stock analysis on TipRanks)ACADIA Pharmaceuticals (ACAD)Last on our list is ACADIA, a biopharmaceutical company that designs medications for central nervous system disorders. ACADIA has developed the only approved therapy for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis, NUPLAZID.Despite COVID-19, sales of NUPLAZID increased 43% to reach $90.1 million for the three months ended March 31, 2020, compared to $63 million in the first quarter of 2019. In addition, management announced it completed a pre-sNDA meeting (a meeting between a company and the FDA to ensure the submission of a well-organized NDA), and is on-track to submit a supplemental NDA this summer for NUPLAZID as a potential breakthrough therapy for DRP (drug related problems) and MDD (major depressive disorder).5-star analyst Charles Duncan, representing Cantor Fitzgerald, viewed management’s announcement positively. In a recent research note, he cited the company’s positive outlook as a major component of his bullish thesis. “Pipeline driven potential is more than additive to our view that NUPLAZID is continuing to gain traction on volume growth by increasing penetration and persistence,” he stated.To this end, Duncan has an Overweight (i.e. Buy) rating on the stock. Along with his rating, the analyst gave the price target a lift, from $58 to $63, implying 34% upside potential. (To watch Duncan’s track record, click here).Other analysts on the Street agree with Duncan and also have high expectations for the stock, with 9 Buys and 1 Hold resulting in a Strong Buy consensus rating. The average price target is $60.30, which implies upside potential of 27%. (See ACADIA stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
- 06/17/2020
|
ABIOMED Unveils Digital Platform CAMP PCI for CAD Treatment
- ABIOMED's (ABMD) new digital platform helps to deliver better patient outcomes for those suffering from CAD.
- 06/17/2020
|
CDKL5 Deficiency Disorder Voice of the Patient Report Submitted to FDA
- PHILADELPHIA NEEDS DATELINE — Understanding the patient voice is fundamental for therapy development. Companies need to ensure that what matters most to patients is being assessed, and regula…
- 06/17/2020
|
CDKL5 Deficiency Disorder Voice of the Patient Report Submitted to FDA
- A report to the FDA describing the voices of patients living with the rare neurological disorder, CDKL5 Deficiency Disorder, was released today.
- 06/17/2020
|
AMN Healthcare (AMN) Introduces New Customizable Offering
- AMN Healthcare (AMN) offers a customizable return-to-work solutions as businesses resume operations amid the ongoing pandemic.
- 06/16/2020
|
Here's Why You Should Add AngioDynamics to Your Portfolio
- AngioDynamics (ANGO) continues to benefit from strategic buyouts and strong product portfolio.
- 06/15/2020
|
HMS Holdings' Solution to Help Consumers Amid Coronavirus
- HMS Holdings (HMSY) offers a unique COVID-19 health management and communications solution to support consumers during the pandemic.
- 06/15/2020
|
Here's Why You Should Add LabCorp (LH) Stock to Your Portfolio
- Investors continue to be optimistic about LabCorp (LH) on increasing demand for COVID-19 tests as well as robust first-quarter 2020 results.
- 06/15/2020
|
Natural Gas: Warmer Than Normal Outlook For End Of June
- Near-term losses in cooling demand push prices lower. But warmer than normal weather could appear at month-end. Lower production and higher power burn demand sh
- 06/12/2020
|
5 PEG-Based Value Stocks to Buy Amid the Coronavirus Crisis
- While P/E alone fails to identify a true value stock, PEG helps to find the intrinsic value of a stock.
- 06/12/2020
|
Shares of several healthcare companies are trading lower in sympathy with the overall market following an increase in coronavirus cases in some US states that have reopened, leading to concerns of a second wave of the virus.
|
Adaptive Biotechnologies and Microsoft launch groundbreaking ImmuneCODE database to share populationwide immune response to the COVID-19 virus
- Adaptive Biotechnologies Corp. (Nasdaq: ADPT) on Thursday launched ImmuneCODE with Microsoft Corp. (Nasdaq: MSFT) to begin sharing one of the largest, most detailed views of the immune response to COVID-19 in real time based on de-identified data generated from thousands of COVID-19 blood samples from patients around the globe. The open database contains detailed information on the extraordinarily diverse set of T cells shown to specifically recognize unique features of the COVID-19 virus, called antigens, with unprecedented speed and scale. T cells contain a treasure trove of information that could provide one consistent and trackable measure of the immune response. This could help diagnose and manage COVID-19 from exposure through clearance of the virus, and potentially offer an accurate assessment of immunity. Data from ImmuneCODE will accelerate ongoing global efforts to develop better diagnostics, vaccines and therapeutics and answer important questions about the virus to support initiatives to safely reopen society.
- 06/11/2020
|
Edo, Ondo gov’ships: INEC won’t declare results if politicians disrupt processes — Yakubu
- Ahead of the September 19 and October 10 governorship elections in Edo and Ondo states respectively, the Independent National Electoral Commission (INEC) has warned politicians planning to undermin…
- 06/11/2020
|
Edo, Ondo gov’ship: INEC reads riot act to politicians
- Ahead of the 19th September and 10th October governorship elections in Edo and Ondo states respectively, the Independent National Electoral Commission (INEC) has read the riot act to politicians pl…
- 06/10/2020
|
Edo/Ondo: ‘Election results won't be declared if politicians disrupt process'
- Chairman of INEC, Professor Mahmood Yakubu has read the riot to act to politicians in Edo planning to undermine or disrupt the process.
- 06/10/2020
|
No Winner Will Emerge If Edo, Ondo Gov Polls Are Disrupted - INEC Warns | Naija News
- Speaking during the meeting, the Nigerian electoral empire boss, Mahmood Yakubu, said the commission will not worry itself to announce a winner after the polls if the process is tempered with.
- 06/10/2020
|
Offres d’emploi du Forem en Wallonie Picarde
- Offres accessibles à tous sans discrimination.
- 06/09/2020
|
COVID-19 Impact and Recovery Analysis- Pharmaceutical Contract Research and Manufacturing Market 2020-2024 | Advent of Big Data to Boost Growth | Technavio
- The Global Pharmaceutical Contract Research and Manufacturing (CRAM) Market will grow by USD 69.09 bn during 2020-2024
- 06/09/2020
|
Baird Maintains Outperform on Laboratory Corp, Raises Price Target to $219
|
U.S. FDA authorizes COVID-19 saliva test by Phosphorus Diagnostics
- The U.S. Food and Drug Administration on Monday allowed emergency use of a COVID-19 saliva test made by privately held Phosphorus Diagnostics LLC that allows people to send in their saliva samples to the company's laboratory for testing. The company's sample collection kit, priced at around $140, would be delivered to customers if they are found eligible after completing an online questionnaire. Test results are expected to be made available within 72 hours after the company's laboratory in Secaucus, New Jersey gets the sample, Phosphorus said.
- 06/08/2020
|
The Strongest Stocks To Buy Now
- Risk of a 3% to 5% correction is increasing. Here's what you can do to position yourself now. The best sectors and stocks to buy.
- 06/06/2020
|
LabCorp's New Website Offers Patients Coronavirus Trial Details
- LabCorp's (LH) Covance business benefits from collaborations with leading pharmaceutical and biotechnology companies.
- 06/04/2020
|
Top 6 Buys of Bernard Horn's Polaris Fund in the 1st Quarter
- Fund’s buys include boost in Tyson and five new holdings Continue reading...
- 06/03/2020
|
$3.72 Bn Bioanalytical Testing Services Market by Type, Application, End-user and Region - Forecast to 2025
- Dublin, June 03, Jun 03, 2020 (GLOBE NEWSWIRE via COMTEX) --
Dublin, June 03, 2020 (GLOBE NEWSWIRE) -- The "Bioanalytical Testing Services Market by Type,...
- 06/03/2020
|
Top 6 Buys of Bernard Horn's Polaris Fund in the –st Quarter
|
Surging Earnings Estimates Signal Upside for LabCorp (LH) Stock
- LabCorp (LH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 06/02/2020
|
These stocks are best positioned to benefit from a coming Covid-19 testing surge, Jefferies says
- Expansion in U.S. Covid-19 testing capabilities will benefit a handful of companies and reveal a new, $60 billion market, Jefferies says.
- 06/02/2020
|
LH vs. ALGN: Which Stock Should Value Investors Buy Now?
- LH vs. ALGN: Which Stock Is the Better Value Option?
- 06/02/2020
|
Deutsche Bank Reinstates Buy on Laboratory Corp, Announces $210 Price Target
|
« Paris peut rouvrir quasiment 100 % des écoles, mais ne pourra pas accueillir 100 % des écoliers »
- Patrick Bloche, adjoint au maire de Paris chargé de l’éducation, défend la politique menée dans la capitale, critiquée par le gouvernement.
- 06/02/2020
|
Polaris Global Value Fund Buys Tyson Foods Inc, HeidelbergCement AG, Laboratory Corp of America ...
|
LabCorp Launches a Website to Inform People on How to Participate in Coronavirus Research
|
LabCorp Launches New COVID-19 Clinical Trial Site to Connect Patients With U.S. Research Trials
- LabCorp (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that Covance, its drug development business, has created COVID-19 Clinical Trial Connect in the U.S., a site designed to help people access information about how to participate in COVID-19 research.
- 06/01/2020
|
LabCorp Launches New COVID-–9 Clinical Trial Site to Connect Patients With U.S. Research Trials
|
Laboratory Corp. of America Holdings (LH): Are Hedge Funds Right About This Stock?
- In this article we will check out the progression of hedge fund sentiment towards Laboratory Corp. of America Holdings (NYSE:LH) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their […]
- 05/29/2020
|
LabCorp (LH) Up 6.8% Since Last Earnings Report: Can It Continue?
- LabCorp (LH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- 05/29/2020
|
LabCorp Partners With Medable to Expand Technology Ecosystem
- LabCorp (LH) expands technology ecosystem to accelerate the adoption of decentralized clinical trials by collaborating with Medable.
- 05/29/2020
|
LabCorp Partners With Medable to Expand Technology Ecosystem
|
Coronavirus update: Novartis enters vaccine race as reopenings, testing efforts ramp up
- Pharmaceutical companies on Thursday continued their pursuit of a breakthrough in the fight against the coronavirus pandemic.
- 05/28/2020
|
LabCorp ties up with software provider to expand virtual clinical trials
- Medable's modular software platform will help patients registered with LabCorp's drug development unit Covance to participate in decentralized clinical trials and facilitate remote data collection and engagement between patients, sites and clinical investigators. In recent months, clinical trial service providers have reported a spike in demand for virtual trials as pharmaceutical companies try to prevent the coronavirus outbreak from derailing their drug rollouts.
- 05/28/2020
|
LabCorp Accelerates Adoption of Decentralized Clinical Trials, Expands Technology Ecosystem Through Alliance With Medable
- LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that Covance, its drug development business, is expanding its technology ecosystem to accelerate the adoption of decentralized clinical trials, often referred to as hybrid and virtual clinical trials.
- 05/28/2020
|
Laboratory Corp. of America Holdings (NYSE:LH) Holdings Lifted by South Dakota Investment Council
- South Dakota Investment Council boosted its position in shares of Laboratory Corp. of America Holdings (NYSE:LH) by 24.6% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,074 shares of the medical research company’s stock after buying an additional 1,791 shares during the quarter. […]
- 05/27/2020
|
Quest Diagnostics rolls out return-to-work services
- Quest Diagnostics is offering companies of all sizes a package of services that include on-site temperature checks, antibody or swab testing.
- 05/27/2020
|
Anatomic Pathology Market Clinical Research Analysis 2020 – 2025 :Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings
- May 25, 2020 (Market Insight Reports) --
Global Anatomic Pathology Market Research Report Forecast 2020 – 2025 is a valuable source of insightful data for...
- 05/25/2020
|
Cardiac Safety Services Market Global Projection, Developments Status, Analysis, Trends, Strategic Assessment By 2026
- May 25, 2020 (CDN Newswire via Comtex) --
Cardiac Safety Services Market Summary: The report studies the Cardiac Safety Services Market 2020 based on the...
- 05/25/2020
|
Richard Snow Buys Into Tyson and Reduces Dow in 1st Quarter
- Guru's top buys and sells Continue reading...
- 05/22/2020
|
Richard Snow Buys Into Tyson and Reduces Dow in –st Quarter
|
SunTrust Robinson Humphrey Maintains Buy on Laboratory Corp, Raises Price Target to $220
|
Laboratory Corp Of America shares are trading higher after Morgan Stanley maintained an Overweight rating and raised the price target from $241 to $244.
|
Morgan Stanley Maintains Overweight on Laboratory Corp, Raises Price Target to $244
|
Archer Investment Corp Buys Lockheed Martin Corp, Bristol-Myers Squibb Company, Laboratory Corp ...
|
Prêtes à affronter la crise, les agences Pôle emploi rouvrent partiellement dans l’Oise
- Les onze sites du département accueilleront à nouveau du public à partir de ce lundi, sur rendez-vous. De quoi faciliter la vie des demandeu
- 05/17/2020
|
Why Is Everyone Talking About LabCorp Stock?
- Millions of tests for COVID-19 have been performed in the U.S., but experts and politicians continue to emphasize that increased testing for the coronavirus is essential for a safe reopening of the economy. With testing so much in the public discussion now, it's not surprising that leading medical testing companies are getting attention from investors, especially as new COVID-19 tests are being granted emergency use authorization every week. Laboratory Corporation of America (NYSE: LH), or LabCorp as it's known, is one of the biggest diagnostic testing companies in the country and has been in the headlines for coronavirus testing.
- 05/17/2020
|
RPT-U.S. employers wary of coronavirus 'immunity' tests as they move to reopen
- U.S. employers have cooled to the idea of testing workers for possible immunity to the coronavirus as they prepare to reopen factories and other workplaces. Blood tests that check for antibodies to the new coronavirus have been touted by governments and some disease experts as a way to identify people who are less likely to fall ill or infect others. Italian automaker Ferrari NV has made antibody testing central to its “Back on Track” project to restarting factories.
- 05/15/2020
|
REFILE-U.S. employers wary of coronavirus 'immunity' tests as they move to reopen
- U.S. employers have cooled to the idea of testing workers for possible immunity to the coronavirus as they prepare to reopen factories and other workplaces. Blood tests that check for antibodies to the new coronavirus have been touted by governments and some disease experts as a way to identify people who are less likely to fall ill or infect others. Italian automaker Ferrari NV has made antibody testing central to its “Back on Track” project to restarting factories.
- 05/15/2020
|
Mizuho Upgrades Laboratory Corp to Buy, Raises Price Target of $186
|
10 Biggest Price Target Changes For Friday
|
LabCorp Launches COVID-19 Testing Service to Help Workers Get Back on the Job
- Companies will be able to screen their employees for the coronavirus and test them for prior infections with SARS-CoV-2.
- 05/14/2020
|
Coronavirus update: Soaring jobless claims jolt US debate over reopening states
- America’s growing ranks of jobless workers underscored the severe toll the coronavirus pandemic has taken on the world’s largest economy, while heightening a polarizing debate over restarting the U.S. economy.
- 05/14/2020
|
LabCorp to make COVID-19 testing services available at workplaces
- The company said it would provide customized services for workplaces including temperature checks, COVID-19 test collection at offices, access to its at-home sample collection kit, antibody test, as well as flu vaccinations in the fall. LabCorp currently provides lab tests, antibody blood tests that can tell whether a person has ever been infected, as well as kits that allow people to mail in their own nasal swab samples, reducing risks of further transmission. LabCorp said its "return to work" offerings would also include wellness services such as biometric screening.
- 05/14/2020
|
LabCorp Launches Return to Work Services for Employers
- LabCorp (NYSE: LH) announced today it is launching a new return to work service for employers. Many U.S. companies have asked for LabCorp’s assistance as they implement their return to work strategies for the summer and fall. To meet this urgent demand, LabCorp Employer Services provides customized return to work solutions using LabCorp’s trained medical staff for employee check-in health questionnaires, temperature screens, and COVID-19 test collection at the employer site or offsite. The service gives employers access to LabCorp’s COVID-19 testing solutions including its at-home collection test kit, its new fingerstick antibody blood test, and in the fall, flu vaccination services.
- 05/14/2020
|
Asset Planning Services, Ltd. Buys Vanguard Mortgage-Backed Securities ETF, Laboratory Corp of ...
|